User login
Hybrid carotid stents eyed positively
CHICAGO – The next generation of hybrid carotid stents is slowly breathing life into the stagnant field of carotid artery stenting.
The new hybrid stents combine the flexibility of a traditional open-cell, nitinol stent with the stabilization typically offered by a closed-cell stent design. The initial clinical experience is limited, but shows promising results against embolization, Dr. Claudio Schönholzsaid at a symposium on vascular surgery sponsored by Northwestern University.
Last year, Dr. Schönholz and his colleagues at the Medical University of South Carolina in Charleston reported the first-in-man use of the investigational Gore Carotid Stent (W.L. Gore & Associates) (J. Endovasc. Thera. 2014;21:601-4).
As part of the Gore Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis in Patients at Increased Risk for Adverse Events From Carotid Endarterectomy (SCAFFOLD) trial, the team has successfully treated another four patients with no evidence of peri- or postprocedural neurological events. This included a case with such severe high-grade stenosis and slow flow that the external carotid artery was not even visible on imaging before the stent was placed, Dr. Schönholz said.
The Food and Drug Administration recently reviewed unreleased data for the first 100 patients enrolled in SCAFFOLD and given the green light for the multicenter, 312-patient study to resume with the start of the new year, he said.Cristallo study (J. Endovasc. Ther. 2008;15:186-92).
A more recent retrospective study revealed only one minor stroke in the perioperative period and during the first 30 days in 68 patients with symptomatic carotid stenosis treated by Turkish surgeons with the Cristallo Ideale stent and a proximal protection device (MO.MA, Invatec s.r.l., Medtronic, Italy) (Int. Angiol. 2014 Nov. 14. [Epub ahead of print]).
Better patient selection, increased operator experience, and use of embolic protection devices has reduced neurological events associated with carotid artery stenting, but embolization still occurs after protection devices are removed due to plaque protrusion through the stent struts, Dr. Schönholz said. The unique design of the hybrid stents “may prevent plaque protrusion, eliminating peri- and postprocedural events,” he said.The Cristallo Ideale hybrid stent is a nitinol-based stent that has a closed-cell portion at its center and an open-cell configuration on the distal and proximal sections. In contrast, the Gore Carotid Stent has a closed-cell component throughout the entire device length that is created by placing an expanded polytetrafluoroethylene lattice with 500-micrometer pores over an open-cell frame. Once combined, both the stent frame and lattice are coated on all surfaces with Carmeda Bioactive Surface (CBAS) heparin. It’s action is limited only to the device surface and has no systemic anticoagulation effects, said Dr. Schönholz, who disclosed serving on Gore’s scientific advisory board.
The open-cell frame allows a high degree of flexibility and conformity to the native anatomy, while the stent lattice provides a high degree of plaque scaffolding that can reduce plaque prolapse, he said. The lattice also reduces the amount of emboli released during and after stent deployment and stabilizes the stent frame by resisting elongation as well as “fish-scaling,” or the misalignment of stent struts that protrude into the vessel wall, particularly when stents are deployed in tortuous anatomy.
Course director Dr. Mark K. Eskandari, chief of vascular surgery at Northwestern University in Chicago, said the results show that “carotid stenting isn’t dead yet and we can persevere. Advances in technology, both in regards to mechanical embolic protection devices and stent design systems, continue to improve the already great results of carotid artery stenting.”
CHICAGO – The next generation of hybrid carotid stents is slowly breathing life into the stagnant field of carotid artery stenting.
The new hybrid stents combine the flexibility of a traditional open-cell, nitinol stent with the stabilization typically offered by a closed-cell stent design. The initial clinical experience is limited, but shows promising results against embolization, Dr. Claudio Schönholzsaid at a symposium on vascular surgery sponsored by Northwestern University.
Last year, Dr. Schönholz and his colleagues at the Medical University of South Carolina in Charleston reported the first-in-man use of the investigational Gore Carotid Stent (W.L. Gore & Associates) (J. Endovasc. Thera. 2014;21:601-4).
As part of the Gore Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis in Patients at Increased Risk for Adverse Events From Carotid Endarterectomy (SCAFFOLD) trial, the team has successfully treated another four patients with no evidence of peri- or postprocedural neurological events. This included a case with such severe high-grade stenosis and slow flow that the external carotid artery was not even visible on imaging before the stent was placed, Dr. Schönholz said.
The Food and Drug Administration recently reviewed unreleased data for the first 100 patients enrolled in SCAFFOLD and given the green light for the multicenter, 312-patient study to resume with the start of the new year, he said.Cristallo study (J. Endovasc. Ther. 2008;15:186-92).
A more recent retrospective study revealed only one minor stroke in the perioperative period and during the first 30 days in 68 patients with symptomatic carotid stenosis treated by Turkish surgeons with the Cristallo Ideale stent and a proximal protection device (MO.MA, Invatec s.r.l., Medtronic, Italy) (Int. Angiol. 2014 Nov. 14. [Epub ahead of print]).
Better patient selection, increased operator experience, and use of embolic protection devices has reduced neurological events associated with carotid artery stenting, but embolization still occurs after protection devices are removed due to plaque protrusion through the stent struts, Dr. Schönholz said. The unique design of the hybrid stents “may prevent plaque protrusion, eliminating peri- and postprocedural events,” he said.The Cristallo Ideale hybrid stent is a nitinol-based stent that has a closed-cell portion at its center and an open-cell configuration on the distal and proximal sections. In contrast, the Gore Carotid Stent has a closed-cell component throughout the entire device length that is created by placing an expanded polytetrafluoroethylene lattice with 500-micrometer pores over an open-cell frame. Once combined, both the stent frame and lattice are coated on all surfaces with Carmeda Bioactive Surface (CBAS) heparin. It’s action is limited only to the device surface and has no systemic anticoagulation effects, said Dr. Schönholz, who disclosed serving on Gore’s scientific advisory board.
The open-cell frame allows a high degree of flexibility and conformity to the native anatomy, while the stent lattice provides a high degree of plaque scaffolding that can reduce plaque prolapse, he said. The lattice also reduces the amount of emboli released during and after stent deployment and stabilizes the stent frame by resisting elongation as well as “fish-scaling,” or the misalignment of stent struts that protrude into the vessel wall, particularly when stents are deployed in tortuous anatomy.
Course director Dr. Mark K. Eskandari, chief of vascular surgery at Northwestern University in Chicago, said the results show that “carotid stenting isn’t dead yet and we can persevere. Advances in technology, both in regards to mechanical embolic protection devices and stent design systems, continue to improve the already great results of carotid artery stenting.”
CHICAGO – The next generation of hybrid carotid stents is slowly breathing life into the stagnant field of carotid artery stenting.
The new hybrid stents combine the flexibility of a traditional open-cell, nitinol stent with the stabilization typically offered by a closed-cell stent design. The initial clinical experience is limited, but shows promising results against embolization, Dr. Claudio Schönholzsaid at a symposium on vascular surgery sponsored by Northwestern University.
Last year, Dr. Schönholz and his colleagues at the Medical University of South Carolina in Charleston reported the first-in-man use of the investigational Gore Carotid Stent (W.L. Gore & Associates) (J. Endovasc. Thera. 2014;21:601-4).
As part of the Gore Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis in Patients at Increased Risk for Adverse Events From Carotid Endarterectomy (SCAFFOLD) trial, the team has successfully treated another four patients with no evidence of peri- or postprocedural neurological events. This included a case with such severe high-grade stenosis and slow flow that the external carotid artery was not even visible on imaging before the stent was placed, Dr. Schönholz said.
The Food and Drug Administration recently reviewed unreleased data for the first 100 patients enrolled in SCAFFOLD and given the green light for the multicenter, 312-patient study to resume with the start of the new year, he said.Cristallo study (J. Endovasc. Ther. 2008;15:186-92).
A more recent retrospective study revealed only one minor stroke in the perioperative period and during the first 30 days in 68 patients with symptomatic carotid stenosis treated by Turkish surgeons with the Cristallo Ideale stent and a proximal protection device (MO.MA, Invatec s.r.l., Medtronic, Italy) (Int. Angiol. 2014 Nov. 14. [Epub ahead of print]).
Better patient selection, increased operator experience, and use of embolic protection devices has reduced neurological events associated with carotid artery stenting, but embolization still occurs after protection devices are removed due to plaque protrusion through the stent struts, Dr. Schönholz said. The unique design of the hybrid stents “may prevent plaque protrusion, eliminating peri- and postprocedural events,” he said.The Cristallo Ideale hybrid stent is a nitinol-based stent that has a closed-cell portion at its center and an open-cell configuration on the distal and proximal sections. In contrast, the Gore Carotid Stent has a closed-cell component throughout the entire device length that is created by placing an expanded polytetrafluoroethylene lattice with 500-micrometer pores over an open-cell frame. Once combined, both the stent frame and lattice are coated on all surfaces with Carmeda Bioactive Surface (CBAS) heparin. It’s action is limited only to the device surface and has no systemic anticoagulation effects, said Dr. Schönholz, who disclosed serving on Gore’s scientific advisory board.
The open-cell frame allows a high degree of flexibility and conformity to the native anatomy, while the stent lattice provides a high degree of plaque scaffolding that can reduce plaque prolapse, he said. The lattice also reduces the amount of emboli released during and after stent deployment and stabilizes the stent frame by resisting elongation as well as “fish-scaling,” or the misalignment of stent struts that protrude into the vessel wall, particularly when stents are deployed in tortuous anatomy.
Course director Dr. Mark K. Eskandari, chief of vascular surgery at Northwestern University in Chicago, said the results show that “carotid stenting isn’t dead yet and we can persevere. Advances in technology, both in regards to mechanical embolic protection devices and stent design systems, continue to improve the already great results of carotid artery stenting.”
Cyber Thieves Exploiting Health Care Security Gaps
CHICAGO – Health care data theft represents a far greater threat than theft of credit card, financial, and banking information.
The reasons are simple: stolen health care records have a longer shelf life and offer a higher payout on the black market, James Trainor, deputy assistant director of the Federal Bureau of Investigation’s Cyber Division, said at the annual meeting of the Healthcare Information Management Systems Society.
When credit cards are stolen it’s pretty easy to identify the information on cyber crime forums and compensate for loss, so the value of that stolen credit card or bank record has a certain shelf life. For health care records, it’s harder to identify where those stolen records may end up and as such it creates a greater challenge for law enforcement.
The opportunity to exploit and monetize stolen health care data for various forms of fraud such as identity, Medicaid, tax, medical device, and pharmaceutical fraud increases the value at which they can be sold online.
“Actually, it’s one of the primary reasons why criminal organizations go after health care records,” Mr. Trainor said.
Not surprisingly, the FBI rates health care data theft as a Tier 1 priority, capable of causing “catastrophic or severe harm.”
And the problem is growing. Two years ago, a significant cyber intrusion occurred every 2 weeks; now it happens every 2-3 days.
“The pace is growing rapidly, the volume of data that’s being [stolen] is substantially increasing, and it just requires a much more robust response across the U.S. government and private sector,” said Mr. Trainor, who helped investigate the December 2014 Sony cyber attack.
Some of the unique challenges to the health care sector are the use of legacy computer systems, “bring your own device” policies, and increased volume of data following the transition to electronic health records, and stolen protected health information isn’t readily discovered, he said. The range, size, and capability of IT infrastructure varies dramatically as do the funding and resources needed to keep up with the rapidly changing IT field.
Other challenges include video conferencing systems, digital video systems used for consultations and remote procedures, and Internet-connected medical devices such as insulin pumps, pacemakers, and MRI machines, said Kevin Hemsley, a project manager at the Idaho National Laboratory supporting the Department of Homeland Security’s Industrial Control Systems Computer Emergency Response Team.
While providers love the ability to use the Internet to control and monitor devices, ingrained security mechanisms can be minimal. This makes for low-hanging fruit for thieves who can enter the system and even lock up an otherwise safe device.
Mr. Hemsley noted that a 2014 report by the Internet security and training firm SANS found that 33% of malicious traffic passed through or was transmitted from VPN applications and devices versus 16% from firewalls, 7% from routers, and 3% from enterprise network controllers.
“One of the messages here is to look at cyber security as being more than HIPPA, it’s patient safety,” he said.
Both experts advised physicians and other health care providers to update their privacy and security software frequently. Available resources include the FBI’s 24-hour CyWatch (855-292-3937/[email protected]), Cyber Task Force (with 56 local field offices), and for individuals, the Internet Crime Complaint Center (www.ic3.gov).
Speedy communication with officials following a data breech is important not just to get the institution’s system back up and running, but it allows officials to identify data footprints left by hackers before they are destroyed, Mr. Trainor said.
In two of the three recent high profile health care cyber attacks involving Community Health Systems (4.5 million accounts), Anthem Blue Cross Blue Shield (78 million records), and Premera Blue Cross (11 million consumers), the institutions contacted the FBI, but in one unnamed case, the FBI had to make the call, he pointed out.
CHICAGO – Health care data theft represents a far greater threat than theft of credit card, financial, and banking information.
The reasons are simple: stolen health care records have a longer shelf life and offer a higher payout on the black market, James Trainor, deputy assistant director of the Federal Bureau of Investigation’s Cyber Division, said at the annual meeting of the Healthcare Information Management Systems Society.
When credit cards are stolen it’s pretty easy to identify the information on cyber crime forums and compensate for loss, so the value of that stolen credit card or bank record has a certain shelf life. For health care records, it’s harder to identify where those stolen records may end up and as such it creates a greater challenge for law enforcement.
The opportunity to exploit and monetize stolen health care data for various forms of fraud such as identity, Medicaid, tax, medical device, and pharmaceutical fraud increases the value at which they can be sold online.
“Actually, it’s one of the primary reasons why criminal organizations go after health care records,” Mr. Trainor said.
Not surprisingly, the FBI rates health care data theft as a Tier 1 priority, capable of causing “catastrophic or severe harm.”
And the problem is growing. Two years ago, a significant cyber intrusion occurred every 2 weeks; now it happens every 2-3 days.
“The pace is growing rapidly, the volume of data that’s being [stolen] is substantially increasing, and it just requires a much more robust response across the U.S. government and private sector,” said Mr. Trainor, who helped investigate the December 2014 Sony cyber attack.
Some of the unique challenges to the health care sector are the use of legacy computer systems, “bring your own device” policies, and increased volume of data following the transition to electronic health records, and stolen protected health information isn’t readily discovered, he said. The range, size, and capability of IT infrastructure varies dramatically as do the funding and resources needed to keep up with the rapidly changing IT field.
Other challenges include video conferencing systems, digital video systems used for consultations and remote procedures, and Internet-connected medical devices such as insulin pumps, pacemakers, and MRI machines, said Kevin Hemsley, a project manager at the Idaho National Laboratory supporting the Department of Homeland Security’s Industrial Control Systems Computer Emergency Response Team.
While providers love the ability to use the Internet to control and monitor devices, ingrained security mechanisms can be minimal. This makes for low-hanging fruit for thieves who can enter the system and even lock up an otherwise safe device.
Mr. Hemsley noted that a 2014 report by the Internet security and training firm SANS found that 33% of malicious traffic passed through or was transmitted from VPN applications and devices versus 16% from firewalls, 7% from routers, and 3% from enterprise network controllers.
“One of the messages here is to look at cyber security as being more than HIPPA, it’s patient safety,” he said.
Both experts advised physicians and other health care providers to update their privacy and security software frequently. Available resources include the FBI’s 24-hour CyWatch (855-292-3937/[email protected]), Cyber Task Force (with 56 local field offices), and for individuals, the Internet Crime Complaint Center (www.ic3.gov).
Speedy communication with officials following a data breech is important not just to get the institution’s system back up and running, but it allows officials to identify data footprints left by hackers before they are destroyed, Mr. Trainor said.
In two of the three recent high profile health care cyber attacks involving Community Health Systems (4.5 million accounts), Anthem Blue Cross Blue Shield (78 million records), and Premera Blue Cross (11 million consumers), the institutions contacted the FBI, but in one unnamed case, the FBI had to make the call, he pointed out.
CHICAGO – Health care data theft represents a far greater threat than theft of credit card, financial, and banking information.
The reasons are simple: stolen health care records have a longer shelf life and offer a higher payout on the black market, James Trainor, deputy assistant director of the Federal Bureau of Investigation’s Cyber Division, said at the annual meeting of the Healthcare Information Management Systems Society.
When credit cards are stolen it’s pretty easy to identify the information on cyber crime forums and compensate for loss, so the value of that stolen credit card or bank record has a certain shelf life. For health care records, it’s harder to identify where those stolen records may end up and as such it creates a greater challenge for law enforcement.
The opportunity to exploit and monetize stolen health care data for various forms of fraud such as identity, Medicaid, tax, medical device, and pharmaceutical fraud increases the value at which they can be sold online.
“Actually, it’s one of the primary reasons why criminal organizations go after health care records,” Mr. Trainor said.
Not surprisingly, the FBI rates health care data theft as a Tier 1 priority, capable of causing “catastrophic or severe harm.”
And the problem is growing. Two years ago, a significant cyber intrusion occurred every 2 weeks; now it happens every 2-3 days.
“The pace is growing rapidly, the volume of data that’s being [stolen] is substantially increasing, and it just requires a much more robust response across the U.S. government and private sector,” said Mr. Trainor, who helped investigate the December 2014 Sony cyber attack.
Some of the unique challenges to the health care sector are the use of legacy computer systems, “bring your own device” policies, and increased volume of data following the transition to electronic health records, and stolen protected health information isn’t readily discovered, he said. The range, size, and capability of IT infrastructure varies dramatically as do the funding and resources needed to keep up with the rapidly changing IT field.
Other challenges include video conferencing systems, digital video systems used for consultations and remote procedures, and Internet-connected medical devices such as insulin pumps, pacemakers, and MRI machines, said Kevin Hemsley, a project manager at the Idaho National Laboratory supporting the Department of Homeland Security’s Industrial Control Systems Computer Emergency Response Team.
While providers love the ability to use the Internet to control and monitor devices, ingrained security mechanisms can be minimal. This makes for low-hanging fruit for thieves who can enter the system and even lock up an otherwise safe device.
Mr. Hemsley noted that a 2014 report by the Internet security and training firm SANS found that 33% of malicious traffic passed through or was transmitted from VPN applications and devices versus 16% from firewalls, 7% from routers, and 3% from enterprise network controllers.
“One of the messages here is to look at cyber security as being more than HIPPA, it’s patient safety,” he said.
Both experts advised physicians and other health care providers to update their privacy and security software frequently. Available resources include the FBI’s 24-hour CyWatch (855-292-3937/[email protected]), Cyber Task Force (with 56 local field offices), and for individuals, the Internet Crime Complaint Center (www.ic3.gov).
Speedy communication with officials following a data breech is important not just to get the institution’s system back up and running, but it allows officials to identify data footprints left by hackers before they are destroyed, Mr. Trainor said.
In two of the three recent high profile health care cyber attacks involving Community Health Systems (4.5 million accounts), Anthem Blue Cross Blue Shield (78 million records), and Premera Blue Cross (11 million consumers), the institutions contacted the FBI, but in one unnamed case, the FBI had to make the call, he pointed out.
EXPERT ANALYSIS FROM HIMSS15
Cyber thieves exploiting health care security gaps
CHICAGO – Health care data theft represents a far greater threat than theft of credit card, financial, and banking information.
The reasons are simple: stolen health care records have a longer shelf life and offer a higher payout on the black market, James Trainor, deputy assistant director of the Federal Bureau of Investigation’s Cyber Division, said at the annual meeting of the Healthcare Information Management Systems Society.
When credit cards are stolen it’s pretty easy to identify the information on cyber crime forums and compensate for loss, so the value of that stolen credit card or bank record has a certain shelf life. For health care records, it’s harder to identify where those stolen records may end up and as such it creates a greater challenge for law enforcement.
The opportunity to exploit and monetize stolen health care data for various forms of fraud such as identity, Medicaid, tax, medical device, and pharmaceutical fraud increases the value at which they can be sold online.
“Actually, it’s one of the primary reasons why criminal organizations go after health care records,” Mr. Trainor said.
Not surprisingly, the FBI rates health care data theft as a Tier 1 priority, capable of causing “catastrophic or severe harm.”
And the problem is growing. Two years ago, a significant cyber intrusion occurred every 2 weeks; now it happens every 2-3 days.
“The pace is growing rapidly, the volume of data that’s being [stolen] is substantially increasing, and it just requires a much more robust response across the U.S. government and private sector,” said Mr. Trainor, who helped investigate the December 2014 Sony cyber attack.
Some of the unique challenges to the health care sector are the use of legacy computer systems, “bring your own device” policies, and increased volume of data following the transition to electronic health records, and stolen protected health information isn’t readily discovered, he said. The range, size, and capability of IT infrastructure varies dramatically as do the funding and resources needed to keep up with the rapidly changing IT field.
Other challenges include video conferencing systems, digital video systems used for consultations and remote procedures, and Internet-connected medical devices such as insulin pumps, pacemakers, and MRI machines, said Kevin Hemsley, a project manager at the Idaho National Laboratory supporting the Department of Homeland Security’s Industrial Control Systems Computer Emergency Response Team.
While providers love the ability to use the Internet to control and monitor devices, ingrained security mechanisms can be minimal. This makes for low-hanging fruit for thieves who can enter the system and even lock up an otherwise safe device.
Mr. Hemsley noted that a 2014 report by the Internet security and training firm SANS found that 33% of malicious traffic passed through or was transmitted from VPN applications and devices versus 16% from firewalls, 7% from routers, and 3% from enterprise network controllers.
“One of the messages here is to look at cyber security as being more than HIPPA, it’s patient safety,” he said.
Both experts advised physicians and other health care providers to update their privacy and security software frequently. Available resources include the FBI’s 24-hour CyWatch (855-292-3937/[email protected]), Cyber Task Force (with 56 local field offices), and for individuals, the Internet Crime Complaint Center (www.ic3.gov).
Speedy communication with officials following a data breech is important not just to get the institution’s system back up and running, but it allows officials to identify data footprints left by hackers before they are destroyed, Mr. Trainor said.
In two of the three recent high profile health care cyber attacks involving Community Health Systems (4.5 million accounts), Anthem Blue Cross Blue Shield (78 million records), and Premera Blue Cross (11 million consumers), the institutions contacted the FBI, but in one unnamed case, the FBI had to make the call, he pointed out.
CHICAGO – Health care data theft represents a far greater threat than theft of credit card, financial, and banking information.
The reasons are simple: stolen health care records have a longer shelf life and offer a higher payout on the black market, James Trainor, deputy assistant director of the Federal Bureau of Investigation’s Cyber Division, said at the annual meeting of the Healthcare Information Management Systems Society.
When credit cards are stolen it’s pretty easy to identify the information on cyber crime forums and compensate for loss, so the value of that stolen credit card or bank record has a certain shelf life. For health care records, it’s harder to identify where those stolen records may end up and as such it creates a greater challenge for law enforcement.
The opportunity to exploit and monetize stolen health care data for various forms of fraud such as identity, Medicaid, tax, medical device, and pharmaceutical fraud increases the value at which they can be sold online.
“Actually, it’s one of the primary reasons why criminal organizations go after health care records,” Mr. Trainor said.
Not surprisingly, the FBI rates health care data theft as a Tier 1 priority, capable of causing “catastrophic or severe harm.”
And the problem is growing. Two years ago, a significant cyber intrusion occurred every 2 weeks; now it happens every 2-3 days.
“The pace is growing rapidly, the volume of data that’s being [stolen] is substantially increasing, and it just requires a much more robust response across the U.S. government and private sector,” said Mr. Trainor, who helped investigate the December 2014 Sony cyber attack.
Some of the unique challenges to the health care sector are the use of legacy computer systems, “bring your own device” policies, and increased volume of data following the transition to electronic health records, and stolen protected health information isn’t readily discovered, he said. The range, size, and capability of IT infrastructure varies dramatically as do the funding and resources needed to keep up with the rapidly changing IT field.
Other challenges include video conferencing systems, digital video systems used for consultations and remote procedures, and Internet-connected medical devices such as insulin pumps, pacemakers, and MRI machines, said Kevin Hemsley, a project manager at the Idaho National Laboratory supporting the Department of Homeland Security’s Industrial Control Systems Computer Emergency Response Team.
While providers love the ability to use the Internet to control and monitor devices, ingrained security mechanisms can be minimal. This makes for low-hanging fruit for thieves who can enter the system and even lock up an otherwise safe device.
Mr. Hemsley noted that a 2014 report by the Internet security and training firm SANS found that 33% of malicious traffic passed through or was transmitted from VPN applications and devices versus 16% from firewalls, 7% from routers, and 3% from enterprise network controllers.
“One of the messages here is to look at cyber security as being more than HIPPA, it’s patient safety,” he said.
Both experts advised physicians and other health care providers to update their privacy and security software frequently. Available resources include the FBI’s 24-hour CyWatch (855-292-3937/[email protected]), Cyber Task Force (with 56 local field offices), and for individuals, the Internet Crime Complaint Center (www.ic3.gov).
Speedy communication with officials following a data breech is important not just to get the institution’s system back up and running, but it allows officials to identify data footprints left by hackers before they are destroyed, Mr. Trainor said.
In two of the three recent high profile health care cyber attacks involving Community Health Systems (4.5 million accounts), Anthem Blue Cross Blue Shield (78 million records), and Premera Blue Cross (11 million consumers), the institutions contacted the FBI, but in one unnamed case, the FBI had to make the call, he pointed out.
CHICAGO – Health care data theft represents a far greater threat than theft of credit card, financial, and banking information.
The reasons are simple: stolen health care records have a longer shelf life and offer a higher payout on the black market, James Trainor, deputy assistant director of the Federal Bureau of Investigation’s Cyber Division, said at the annual meeting of the Healthcare Information Management Systems Society.
When credit cards are stolen it’s pretty easy to identify the information on cyber crime forums and compensate for loss, so the value of that stolen credit card or bank record has a certain shelf life. For health care records, it’s harder to identify where those stolen records may end up and as such it creates a greater challenge for law enforcement.
The opportunity to exploit and monetize stolen health care data for various forms of fraud such as identity, Medicaid, tax, medical device, and pharmaceutical fraud increases the value at which they can be sold online.
“Actually, it’s one of the primary reasons why criminal organizations go after health care records,” Mr. Trainor said.
Not surprisingly, the FBI rates health care data theft as a Tier 1 priority, capable of causing “catastrophic or severe harm.”
And the problem is growing. Two years ago, a significant cyber intrusion occurred every 2 weeks; now it happens every 2-3 days.
“The pace is growing rapidly, the volume of data that’s being [stolen] is substantially increasing, and it just requires a much more robust response across the U.S. government and private sector,” said Mr. Trainor, who helped investigate the December 2014 Sony cyber attack.
Some of the unique challenges to the health care sector are the use of legacy computer systems, “bring your own device” policies, and increased volume of data following the transition to electronic health records, and stolen protected health information isn’t readily discovered, he said. The range, size, and capability of IT infrastructure varies dramatically as do the funding and resources needed to keep up with the rapidly changing IT field.
Other challenges include video conferencing systems, digital video systems used for consultations and remote procedures, and Internet-connected medical devices such as insulin pumps, pacemakers, and MRI machines, said Kevin Hemsley, a project manager at the Idaho National Laboratory supporting the Department of Homeland Security’s Industrial Control Systems Computer Emergency Response Team.
While providers love the ability to use the Internet to control and monitor devices, ingrained security mechanisms can be minimal. This makes for low-hanging fruit for thieves who can enter the system and even lock up an otherwise safe device.
Mr. Hemsley noted that a 2014 report by the Internet security and training firm SANS found that 33% of malicious traffic passed through or was transmitted from VPN applications and devices versus 16% from firewalls, 7% from routers, and 3% from enterprise network controllers.
“One of the messages here is to look at cyber security as being more than HIPPA, it’s patient safety,” he said.
Both experts advised physicians and other health care providers to update their privacy and security software frequently. Available resources include the FBI’s 24-hour CyWatch (855-292-3937/[email protected]), Cyber Task Force (with 56 local field offices), and for individuals, the Internet Crime Complaint Center (www.ic3.gov).
Speedy communication with officials following a data breech is important not just to get the institution’s system back up and running, but it allows officials to identify data footprints left by hackers before they are destroyed, Mr. Trainor said.
In two of the three recent high profile health care cyber attacks involving Community Health Systems (4.5 million accounts), Anthem Blue Cross Blue Shield (78 million records), and Premera Blue Cross (11 million consumers), the institutions contacted the FBI, but in one unnamed case, the FBI had to make the call, he pointed out.
EXPERT ANALYSIS FROM HIMSS15
Commercial board-review courses offer no bang for the buck
CHICAGO – A national survey of 1,246 residents found no evidence that taking a commercial board-review course provides any benefit in passing the American Board of Surgery certifying exam.
And none of the courses was significantly better than another, reported Dr. Mark Malangoni, an ACS Fellow and ABS associate executive director.
“Exam-review courses are now a multibillion-dollar industry … but there is little evidence to suggest they actually improve exam performance,” he said.
Dr. Malangoni and his ABS colleagues electronically surveyed 1,396 candidates who took the ABS certifying exam (CE) during the 2012-2013 academic year. Of the 1,246 who responded, 974 (78%) had taken a review course. Another 140 candidates declined to respond to the two-question survey, but their CE test results were available for comparison.
Among first-time examinees, the CE pass rate was 83.7% with any review course, 80.7% with no course, and 75.6% for the nonresponders, Dr. Malangoni said at the annual meeting of the Central Surgical Association.
Among those who had taken the CE before, pass rates were 77%, 69%, and 58%, respectively, with the intergroup difference statistically significant only for the nonresponders (P value = .01).
Despite the lack of benefit, however, most examinees (64%) believed that the review course improved their preparation for the CE, he said.
Those repeating the CE were significantly more likely than first-time examinees to take a review course (84.6% vs. 76.1%; P = .002).
Several candidates decided that multiple review courses might be better: 16% of the first-time examinees and 32% of the repeat examinees. Again, pass rates were not significantly different with multiple courses, Dr. Malangoni said.
The survey identified nine commercially available courses, but five were not analyzed because there were no enrollees or a low number (≤ 40) of enrollees. The remaining four courses were assigned a letter for anonymity. Enrollment in all courses ranged from 21 to 706 students.
In multivariate analysis, the only significant predictor for passing the initial CE was the qualifying examination scale score (Odds ratio, 1.09; P < .001). Course D trended toward a benefit, but the 99% confidence intervals overlapped and the P value did not meet the predetermined threshold of ≤ .01 (OR, 3.25; P = .02; 99% CI 0.86-12.22), he said.
For repeat examinees, no variables including the four review courses, gender, program size, or international medical graduation significantly predicted success on the CE exam.
“Given the time and effort, and expense, we feel that CE candidates should consider these results when assessing how best to prepare for this examination,” Dr. Malangoni concluded.
The study is not the first to question the benefit of review courses for already cash-strapped medical students and residents (N. Engl. J. Med. 2011:365:104-5), he noted.
Dr. Malangoni balked, however, at suggesting review courses may not be worth the investment for any candidate.
“Our results are applicable to a large group; however, it is not possible to determine when taking a review course would be beneficial for a specific candidate,” he said in an interview.
Dr. Malangoni reported having no financial disclosures.
On Twitter @pwendl
CHICAGO – A national survey of 1,246 residents found no evidence that taking a commercial board-review course provides any benefit in passing the American Board of Surgery certifying exam.
And none of the courses was significantly better than another, reported Dr. Mark Malangoni, an ACS Fellow and ABS associate executive director.
“Exam-review courses are now a multibillion-dollar industry … but there is little evidence to suggest they actually improve exam performance,” he said.
Dr. Malangoni and his ABS colleagues electronically surveyed 1,396 candidates who took the ABS certifying exam (CE) during the 2012-2013 academic year. Of the 1,246 who responded, 974 (78%) had taken a review course. Another 140 candidates declined to respond to the two-question survey, but their CE test results were available for comparison.
Among first-time examinees, the CE pass rate was 83.7% with any review course, 80.7% with no course, and 75.6% for the nonresponders, Dr. Malangoni said at the annual meeting of the Central Surgical Association.
Among those who had taken the CE before, pass rates were 77%, 69%, and 58%, respectively, with the intergroup difference statistically significant only for the nonresponders (P value = .01).
Despite the lack of benefit, however, most examinees (64%) believed that the review course improved their preparation for the CE, he said.
Those repeating the CE were significantly more likely than first-time examinees to take a review course (84.6% vs. 76.1%; P = .002).
Several candidates decided that multiple review courses might be better: 16% of the first-time examinees and 32% of the repeat examinees. Again, pass rates were not significantly different with multiple courses, Dr. Malangoni said.
The survey identified nine commercially available courses, but five were not analyzed because there were no enrollees or a low number (≤ 40) of enrollees. The remaining four courses were assigned a letter for anonymity. Enrollment in all courses ranged from 21 to 706 students.
In multivariate analysis, the only significant predictor for passing the initial CE was the qualifying examination scale score (Odds ratio, 1.09; P < .001). Course D trended toward a benefit, but the 99% confidence intervals overlapped and the P value did not meet the predetermined threshold of ≤ .01 (OR, 3.25; P = .02; 99% CI 0.86-12.22), he said.
For repeat examinees, no variables including the four review courses, gender, program size, or international medical graduation significantly predicted success on the CE exam.
“Given the time and effort, and expense, we feel that CE candidates should consider these results when assessing how best to prepare for this examination,” Dr. Malangoni concluded.
The study is not the first to question the benefit of review courses for already cash-strapped medical students and residents (N. Engl. J. Med. 2011:365:104-5), he noted.
Dr. Malangoni balked, however, at suggesting review courses may not be worth the investment for any candidate.
“Our results are applicable to a large group; however, it is not possible to determine when taking a review course would be beneficial for a specific candidate,” he said in an interview.
Dr. Malangoni reported having no financial disclosures.
On Twitter @pwendl
CHICAGO – A national survey of 1,246 residents found no evidence that taking a commercial board-review course provides any benefit in passing the American Board of Surgery certifying exam.
And none of the courses was significantly better than another, reported Dr. Mark Malangoni, an ACS Fellow and ABS associate executive director.
“Exam-review courses are now a multibillion-dollar industry … but there is little evidence to suggest they actually improve exam performance,” he said.
Dr. Malangoni and his ABS colleagues electronically surveyed 1,396 candidates who took the ABS certifying exam (CE) during the 2012-2013 academic year. Of the 1,246 who responded, 974 (78%) had taken a review course. Another 140 candidates declined to respond to the two-question survey, but their CE test results were available for comparison.
Among first-time examinees, the CE pass rate was 83.7% with any review course, 80.7% with no course, and 75.6% for the nonresponders, Dr. Malangoni said at the annual meeting of the Central Surgical Association.
Among those who had taken the CE before, pass rates were 77%, 69%, and 58%, respectively, with the intergroup difference statistically significant only for the nonresponders (P value = .01).
Despite the lack of benefit, however, most examinees (64%) believed that the review course improved their preparation for the CE, he said.
Those repeating the CE were significantly more likely than first-time examinees to take a review course (84.6% vs. 76.1%; P = .002).
Several candidates decided that multiple review courses might be better: 16% of the first-time examinees and 32% of the repeat examinees. Again, pass rates were not significantly different with multiple courses, Dr. Malangoni said.
The survey identified nine commercially available courses, but five were not analyzed because there were no enrollees or a low number (≤ 40) of enrollees. The remaining four courses were assigned a letter for anonymity. Enrollment in all courses ranged from 21 to 706 students.
In multivariate analysis, the only significant predictor for passing the initial CE was the qualifying examination scale score (Odds ratio, 1.09; P < .001). Course D trended toward a benefit, but the 99% confidence intervals overlapped and the P value did not meet the predetermined threshold of ≤ .01 (OR, 3.25; P = .02; 99% CI 0.86-12.22), he said.
For repeat examinees, no variables including the four review courses, gender, program size, or international medical graduation significantly predicted success on the CE exam.
“Given the time and effort, and expense, we feel that CE candidates should consider these results when assessing how best to prepare for this examination,” Dr. Malangoni concluded.
The study is not the first to question the benefit of review courses for already cash-strapped medical students and residents (N. Engl. J. Med. 2011:365:104-5), he noted.
Dr. Malangoni balked, however, at suggesting review courses may not be worth the investment for any candidate.
“Our results are applicable to a large group; however, it is not possible to determine when taking a review course would be beneficial for a specific candidate,” he said in an interview.
Dr. Malangoni reported having no financial disclosures.
On Twitter @pwendl
AT THE ANNUAL MEETING OF THE CENTRAL SURGICAL ASSOCIATION
Key clinical point: Commercial board-review courses do not improve the likelihood of passing the American Board of Surgery certifying exam.
Major finding: For first-time examinees, the pass rate was 83.7% with a review course, 80.7% with no course, and 75.6% for nonresponders.
Data source: Survey of 1,246 candidates taking the ABS certifying exam.
Disclosures: Dr. Malangoni reported having no financial disclosures.
Health IT Roadmap draws comments
CHICAGO – The federal government’s Shared Nationwide Interoperability Roadmap lays out a grand vision for a single health IT ecosystem, but will it be able to enforce its own standards or be able to meaningfully incorporate the flood of patient-provided data in an era of Fitbits and Apple watches?
Those were just a few of the concerns heard by the officials from the Office of the National Coordinator for Health Information Technology (ONC) at the annual meeting of the Healthcare Information and Management Systems Society.
During a listening session on the Roadmap, one attendee called for oversight and a transparent process to handle complaints much like the airline industry has for lost luggage, observing that providers already have a hard time getting industry to recognize and “play ball” with each other.
Rules of engagement and governance are one of the core building blocks of the Roadmap, with the ONC establishing a governance framework with rules of the road and identifying a mechanism to recognize organizations that comply with that framework. That could be thought of as a mechanism for advancing some accountability, but it’s important to remember that participation in that process will be voluntary, according to Erica Galvez, interoperability portfolio manager at ONC.
“So unless that’s tied to other policy levers ... or other enforcement authorities, ONC, given its current authority, has quite a few limitations on its ability to actually affect the type of enforcement you’re alluding to,” she added.
The ONC does have proposals for in-field surveillance of products and additional transparency requirements associated with products, said Steven Posnack, director of the ONC Office of Standards and Technology. Still, the ONC doesn’t necessarily have all the “arrows and quivers” needed to affect the enforcement and accountability some would like, he acknowledged.
Core technical standards and functions designed to help achieve the Roadmap’s 3-, 6-, and 10-year milestones include consistent data formats and semantics; consistent, secure transport techniques; standard, secure services; accurate patient identity matching; and reliable resource location.
One physician attendee called for standardizing the standards themselves, noting that there are more than 150 terminologies in use, each with its own idiosyncrasies. One approach may be to follow the example set by global IT organizations like Facebook, LinkedIn, and Yahoo, which converged on using the Web standards as a means to have persistent, authoritative URIs (uniform resource identifiers) that can be shared globally, he suggested to a round of applause.
Another attendee called for future drafts of the Roadmap to address an increasing trend among biopharmaceutical companies to create their own portals or mobile apps for a specific therapy, which requires providers to download multiple infrastructures to support various therapies.
Still another attendee artfully asked that Departments of Defense and Veterans Affairs medical records be incorporated into the proposed nationwide IT system to ensure meaningful longitudinal care for veterans.
There was little audience discussion about the Roadmap’s other core building blocks of a common clinical data set or privacy and security. Concerns about medical device interoperability, however, were raised from the floor and have been echoed in the public comments received by the ONC, Ms. Galvez said.
She stressed that the Roadmap is a shared plan that attempts to capture both public and private sector activities.
“We’re not going to achieve interoperability at the scale we are attempting with government action alone,” Ms. Galvez said. “In looking at some of the early public comments, I will say I have not seen as many commitments from folks as I would really like to see. I’d really like to see organizations coming forward and saying ‘There’s a call to action in this space, we think there’s something we can do about that, and here’s what we’re willing to do.’ ”
The public comment period on the Roadmap officially closed April 3, but comments on the ONC’s 2015 Interoperability Standards Advisory will be accepted through May 1.
CHICAGO – The federal government’s Shared Nationwide Interoperability Roadmap lays out a grand vision for a single health IT ecosystem, but will it be able to enforce its own standards or be able to meaningfully incorporate the flood of patient-provided data in an era of Fitbits and Apple watches?
Those were just a few of the concerns heard by the officials from the Office of the National Coordinator for Health Information Technology (ONC) at the annual meeting of the Healthcare Information and Management Systems Society.
During a listening session on the Roadmap, one attendee called for oversight and a transparent process to handle complaints much like the airline industry has for lost luggage, observing that providers already have a hard time getting industry to recognize and “play ball” with each other.
Rules of engagement and governance are one of the core building blocks of the Roadmap, with the ONC establishing a governance framework with rules of the road and identifying a mechanism to recognize organizations that comply with that framework. That could be thought of as a mechanism for advancing some accountability, but it’s important to remember that participation in that process will be voluntary, according to Erica Galvez, interoperability portfolio manager at ONC.
“So unless that’s tied to other policy levers ... or other enforcement authorities, ONC, given its current authority, has quite a few limitations on its ability to actually affect the type of enforcement you’re alluding to,” she added.
The ONC does have proposals for in-field surveillance of products and additional transparency requirements associated with products, said Steven Posnack, director of the ONC Office of Standards and Technology. Still, the ONC doesn’t necessarily have all the “arrows and quivers” needed to affect the enforcement and accountability some would like, he acknowledged.
Core technical standards and functions designed to help achieve the Roadmap’s 3-, 6-, and 10-year milestones include consistent data formats and semantics; consistent, secure transport techniques; standard, secure services; accurate patient identity matching; and reliable resource location.
One physician attendee called for standardizing the standards themselves, noting that there are more than 150 terminologies in use, each with its own idiosyncrasies. One approach may be to follow the example set by global IT organizations like Facebook, LinkedIn, and Yahoo, which converged on using the Web standards as a means to have persistent, authoritative URIs (uniform resource identifiers) that can be shared globally, he suggested to a round of applause.
Another attendee called for future drafts of the Roadmap to address an increasing trend among biopharmaceutical companies to create their own portals or mobile apps for a specific therapy, which requires providers to download multiple infrastructures to support various therapies.
Still another attendee artfully asked that Departments of Defense and Veterans Affairs medical records be incorporated into the proposed nationwide IT system to ensure meaningful longitudinal care for veterans.
There was little audience discussion about the Roadmap’s other core building blocks of a common clinical data set or privacy and security. Concerns about medical device interoperability, however, were raised from the floor and have been echoed in the public comments received by the ONC, Ms. Galvez said.
She stressed that the Roadmap is a shared plan that attempts to capture both public and private sector activities.
“We’re not going to achieve interoperability at the scale we are attempting with government action alone,” Ms. Galvez said. “In looking at some of the early public comments, I will say I have not seen as many commitments from folks as I would really like to see. I’d really like to see organizations coming forward and saying ‘There’s a call to action in this space, we think there’s something we can do about that, and here’s what we’re willing to do.’ ”
The public comment period on the Roadmap officially closed April 3, but comments on the ONC’s 2015 Interoperability Standards Advisory will be accepted through May 1.
CHICAGO – The federal government’s Shared Nationwide Interoperability Roadmap lays out a grand vision for a single health IT ecosystem, but will it be able to enforce its own standards or be able to meaningfully incorporate the flood of patient-provided data in an era of Fitbits and Apple watches?
Those were just a few of the concerns heard by the officials from the Office of the National Coordinator for Health Information Technology (ONC) at the annual meeting of the Healthcare Information and Management Systems Society.
During a listening session on the Roadmap, one attendee called for oversight and a transparent process to handle complaints much like the airline industry has for lost luggage, observing that providers already have a hard time getting industry to recognize and “play ball” with each other.
Rules of engagement and governance are one of the core building blocks of the Roadmap, with the ONC establishing a governance framework with rules of the road and identifying a mechanism to recognize organizations that comply with that framework. That could be thought of as a mechanism for advancing some accountability, but it’s important to remember that participation in that process will be voluntary, according to Erica Galvez, interoperability portfolio manager at ONC.
“So unless that’s tied to other policy levers ... or other enforcement authorities, ONC, given its current authority, has quite a few limitations on its ability to actually affect the type of enforcement you’re alluding to,” she added.
The ONC does have proposals for in-field surveillance of products and additional transparency requirements associated with products, said Steven Posnack, director of the ONC Office of Standards and Technology. Still, the ONC doesn’t necessarily have all the “arrows and quivers” needed to affect the enforcement and accountability some would like, he acknowledged.
Core technical standards and functions designed to help achieve the Roadmap’s 3-, 6-, and 10-year milestones include consistent data formats and semantics; consistent, secure transport techniques; standard, secure services; accurate patient identity matching; and reliable resource location.
One physician attendee called for standardizing the standards themselves, noting that there are more than 150 terminologies in use, each with its own idiosyncrasies. One approach may be to follow the example set by global IT organizations like Facebook, LinkedIn, and Yahoo, which converged on using the Web standards as a means to have persistent, authoritative URIs (uniform resource identifiers) that can be shared globally, he suggested to a round of applause.
Another attendee called for future drafts of the Roadmap to address an increasing trend among biopharmaceutical companies to create their own portals or mobile apps for a specific therapy, which requires providers to download multiple infrastructures to support various therapies.
Still another attendee artfully asked that Departments of Defense and Veterans Affairs medical records be incorporated into the proposed nationwide IT system to ensure meaningful longitudinal care for veterans.
There was little audience discussion about the Roadmap’s other core building blocks of a common clinical data set or privacy and security. Concerns about medical device interoperability, however, were raised from the floor and have been echoed in the public comments received by the ONC, Ms. Galvez said.
She stressed that the Roadmap is a shared plan that attempts to capture both public and private sector activities.
“We’re not going to achieve interoperability at the scale we are attempting with government action alone,” Ms. Galvez said. “In looking at some of the early public comments, I will say I have not seen as many commitments from folks as I would really like to see. I’d really like to see organizations coming forward and saying ‘There’s a call to action in this space, we think there’s something we can do about that, and here’s what we’re willing to do.’ ”
The public comment period on the Roadmap officially closed April 3, but comments on the ONC’s 2015 Interoperability Standards Advisory will be accepted through May 1.
AT HIMSS15
Ablation during mitral valve surgery offers up mixed results
SAN DIEGO – Surgical ablation of atrial fibrillation at the time of mitral valve surgery provides significantly greater rhythm control than mitral valve surgery alone, a study showed.
Freedom from atrial fibrillation (AF) at both 6 months and 1 year was 63% in patients undergoing mitral valve surgery (MVS) plus ablation and 29% in those undergoing MVS alone, a statistically significant difference.
However, patients who had ablation plus MVS were 2.5 times more likely to have a permanent pacemaker implanted than were those who had MVS alone, at 21.5% and 8.1%, respectively, also a significant difference.
Ablation did not increase mortality or major adverse cardiac or cerebrovascular events, Dr. A. Marc Gillinov said at the annual meeting of the American College of Cardiology.
Preoperative AF is present in up to 50% of patients undergoing mitral valve operations and is associated with an increased risk of death and stroke.
The study enrolled 260 relatively elderly patients (mean age 69 years) with AF that was persistent (non–self-terminating for at least 7 days) or long-standing persistent (continuous for at least a year), in addition to mitral valve disease. A total of 133 patients were randomly assigned to MVS plus ablation and 127 to MVS alone. The ablation group was further randomized to pulmonary vein isolation or a biatrial maze procedure; all underwent closure of the left atrial appendage.
There was no significant difference in freedom from AF at 6 months and 1 year between patients who had pulmonary vein isolation or a biatrial maze procedure, at 61% and 66%, respectively, said Dr. Gillinov, a cardiac surgeon at Cleveland Clinic.
One-year mortality was similar among all patients undergoing MVS plus ablation vs. MVS alone, at 6.8% and 8.7%.
The two groups also had similar Short Form-12 questionnaire scores for physical function and mental function, although AF occurring at least once daily was significantly less common with ablation, at 19.8%, compared with 45.2% in the MVS-alone patients, he said.
The heart rhythm endpoint was “stringent,” with 3-day Holter monitors obtained at both 6 and 12 months and repeat ablation procedures and death considered treatment failures, Dr. Gillinov said.
He acknowledged that 20% of patients did not have data for the primary endpoint and that the endpoint was not a clinical one, but said a trial with mortality or stroke as the endpoint would require more than 1,000 patients and many years follow-up.
Regarding whether ablation should now be performed routinely, “the glass is half full or half empty,” remarked discussant Dr. Bernard Gersh of Mayo Clinic in Rochester, Minn. “On one hand, you have shown less atrial fibrillation [with ablation], but no effect on quality of life, and the price to be paid was a higher rate of pacemaker implantation,” he said.
The pacemaker implantation rate was higher than expected – 17% in-hospital – and does represent a potential cost, but he would routinely do a maze procedure, Dr. Gillinov said.
Discussant Dr. Alice Jacobs of the Cardiovascular Center at Boston Medical Center, said she expected Dr. Gillinov to say the procedure should not be used in everyone given the lack of benefit in stroke, probably because they tied off the left atrium appendage, and the increase in pacemaker implantations.
About half of the pacemaker implantations were due to atrioventricular block, possibly a consequence of the valve surgery, and one-third to sinus-node dysfunction, which is common in elderly patients, Dr. Gillinov explained.
The study was funded by the National Institutes of Health and the Canadian Institutes of Health Research. Dr. Gillinov reported serving as a consultant/speaker for AtriCure, Medtronic, On-X, Edwards, and Tendyne; research funding from St. Jude Medical; an equity interest in Clear Catheter; and that his institution receives royalties from AtriCure for a left atrial appendage occlusion device.
SAN DIEGO – Surgical ablation of atrial fibrillation at the time of mitral valve surgery provides significantly greater rhythm control than mitral valve surgery alone, a study showed.
Freedom from atrial fibrillation (AF) at both 6 months and 1 year was 63% in patients undergoing mitral valve surgery (MVS) plus ablation and 29% in those undergoing MVS alone, a statistically significant difference.
However, patients who had ablation plus MVS were 2.5 times more likely to have a permanent pacemaker implanted than were those who had MVS alone, at 21.5% and 8.1%, respectively, also a significant difference.
Ablation did not increase mortality or major adverse cardiac or cerebrovascular events, Dr. A. Marc Gillinov said at the annual meeting of the American College of Cardiology.
Preoperative AF is present in up to 50% of patients undergoing mitral valve operations and is associated with an increased risk of death and stroke.
The study enrolled 260 relatively elderly patients (mean age 69 years) with AF that was persistent (non–self-terminating for at least 7 days) or long-standing persistent (continuous for at least a year), in addition to mitral valve disease. A total of 133 patients were randomly assigned to MVS plus ablation and 127 to MVS alone. The ablation group was further randomized to pulmonary vein isolation or a biatrial maze procedure; all underwent closure of the left atrial appendage.
There was no significant difference in freedom from AF at 6 months and 1 year between patients who had pulmonary vein isolation or a biatrial maze procedure, at 61% and 66%, respectively, said Dr. Gillinov, a cardiac surgeon at Cleveland Clinic.
One-year mortality was similar among all patients undergoing MVS plus ablation vs. MVS alone, at 6.8% and 8.7%.
The two groups also had similar Short Form-12 questionnaire scores for physical function and mental function, although AF occurring at least once daily was significantly less common with ablation, at 19.8%, compared with 45.2% in the MVS-alone patients, he said.
The heart rhythm endpoint was “stringent,” with 3-day Holter monitors obtained at both 6 and 12 months and repeat ablation procedures and death considered treatment failures, Dr. Gillinov said.
He acknowledged that 20% of patients did not have data for the primary endpoint and that the endpoint was not a clinical one, but said a trial with mortality or stroke as the endpoint would require more than 1,000 patients and many years follow-up.
Regarding whether ablation should now be performed routinely, “the glass is half full or half empty,” remarked discussant Dr. Bernard Gersh of Mayo Clinic in Rochester, Minn. “On one hand, you have shown less atrial fibrillation [with ablation], but no effect on quality of life, and the price to be paid was a higher rate of pacemaker implantation,” he said.
The pacemaker implantation rate was higher than expected – 17% in-hospital – and does represent a potential cost, but he would routinely do a maze procedure, Dr. Gillinov said.
Discussant Dr. Alice Jacobs of the Cardiovascular Center at Boston Medical Center, said she expected Dr. Gillinov to say the procedure should not be used in everyone given the lack of benefit in stroke, probably because they tied off the left atrium appendage, and the increase in pacemaker implantations.
About half of the pacemaker implantations were due to atrioventricular block, possibly a consequence of the valve surgery, and one-third to sinus-node dysfunction, which is common in elderly patients, Dr. Gillinov explained.
The study was funded by the National Institutes of Health and the Canadian Institutes of Health Research. Dr. Gillinov reported serving as a consultant/speaker for AtriCure, Medtronic, On-X, Edwards, and Tendyne; research funding from St. Jude Medical; an equity interest in Clear Catheter; and that his institution receives royalties from AtriCure for a left atrial appendage occlusion device.
SAN DIEGO – Surgical ablation of atrial fibrillation at the time of mitral valve surgery provides significantly greater rhythm control than mitral valve surgery alone, a study showed.
Freedom from atrial fibrillation (AF) at both 6 months and 1 year was 63% in patients undergoing mitral valve surgery (MVS) plus ablation and 29% in those undergoing MVS alone, a statistically significant difference.
However, patients who had ablation plus MVS were 2.5 times more likely to have a permanent pacemaker implanted than were those who had MVS alone, at 21.5% and 8.1%, respectively, also a significant difference.
Ablation did not increase mortality or major adverse cardiac or cerebrovascular events, Dr. A. Marc Gillinov said at the annual meeting of the American College of Cardiology.
Preoperative AF is present in up to 50% of patients undergoing mitral valve operations and is associated with an increased risk of death and stroke.
The study enrolled 260 relatively elderly patients (mean age 69 years) with AF that was persistent (non–self-terminating for at least 7 days) or long-standing persistent (continuous for at least a year), in addition to mitral valve disease. A total of 133 patients were randomly assigned to MVS plus ablation and 127 to MVS alone. The ablation group was further randomized to pulmonary vein isolation or a biatrial maze procedure; all underwent closure of the left atrial appendage.
There was no significant difference in freedom from AF at 6 months and 1 year between patients who had pulmonary vein isolation or a biatrial maze procedure, at 61% and 66%, respectively, said Dr. Gillinov, a cardiac surgeon at Cleveland Clinic.
One-year mortality was similar among all patients undergoing MVS plus ablation vs. MVS alone, at 6.8% and 8.7%.
The two groups also had similar Short Form-12 questionnaire scores for physical function and mental function, although AF occurring at least once daily was significantly less common with ablation, at 19.8%, compared with 45.2% in the MVS-alone patients, he said.
The heart rhythm endpoint was “stringent,” with 3-day Holter monitors obtained at both 6 and 12 months and repeat ablation procedures and death considered treatment failures, Dr. Gillinov said.
He acknowledged that 20% of patients did not have data for the primary endpoint and that the endpoint was not a clinical one, but said a trial with mortality or stroke as the endpoint would require more than 1,000 patients and many years follow-up.
Regarding whether ablation should now be performed routinely, “the glass is half full or half empty,” remarked discussant Dr. Bernard Gersh of Mayo Clinic in Rochester, Minn. “On one hand, you have shown less atrial fibrillation [with ablation], but no effect on quality of life, and the price to be paid was a higher rate of pacemaker implantation,” he said.
The pacemaker implantation rate was higher than expected – 17% in-hospital – and does represent a potential cost, but he would routinely do a maze procedure, Dr. Gillinov said.
Discussant Dr. Alice Jacobs of the Cardiovascular Center at Boston Medical Center, said she expected Dr. Gillinov to say the procedure should not be used in everyone given the lack of benefit in stroke, probably because they tied off the left atrium appendage, and the increase in pacemaker implantations.
About half of the pacemaker implantations were due to atrioventricular block, possibly a consequence of the valve surgery, and one-third to sinus-node dysfunction, which is common in elderly patients, Dr. Gillinov explained.
The study was funded by the National Institutes of Health and the Canadian Institutes of Health Research. Dr. Gillinov reported serving as a consultant/speaker for AtriCure, Medtronic, On-X, Edwards, and Tendyne; research funding from St. Jude Medical; an equity interest in Clear Catheter; and that his institution receives royalties from AtriCure for a left atrial appendage occlusion device.
AT ACC 15
Key clinical point: Surgical ablation of atrial fibrillation during mitral valve surgery decreases AF at 6 months and 1 year, but increases pacemaker implantations.
Major finding: Freedom from AF at both 6 months and 1 year was 63% with mitral valve surgery plus ablation and 29% for MVS alone.
Data source: Prospective, randomized study in 260 patients with persistent or longstanding persistent AF who required mitral valve surgery.
Disclosures: The study was funded by the National Institutes of Health and the Canadian Institutes of Health Research. Dr. Gillinov reported serving as a consultant/speaker for AtriCure, Medtronic, On-X, Edwards, and Tendyne; research funding from St. Jude Medical; an equity interest in Clear Catheter; and that his institution receives royalties from AtriCure for a left atrial appendage occlusion device.
Costs a wash between CTA and functional chest pain testing
SAN DIEGO– After the first 90 days, there is very little difference in costs out to 3 years between CT angiography and functional testing in the initial evaluation of stable patients with new chest pain, an economic substudy of the PROMISE trial showed.
“CT coronary angiography may not be the ‘holy grail’ of diagnostic tests that we once envisioned, but its more liberal use based on the results of PROMISE may improve some aspects of patient care and I don’t think will be a major new economic burden on the health care system,” study author Dr. Daniel B. Mark said at the annual meeting of the American College of Cardiology.
The PROMISE trial, also presented at the ACA meeting, found no advantage with respect to hard clinical outcomes between the two initial testing strategies, but CTA led to fewer catheterizations showing no obstructive disease and a twofold increase in revascularizations.
The economic analysis involved initial test technical fees, hospital-based facility costs, and physician professional fees for testing and hospital services for 96% of the 9,649 patients in the study.
The estimated cost of CT angiography, including physician fees and technical fees, was $404, compared with $174 for exercise treadmill testing, $501 for echocardiography with pharmacologic stress, $514 for echo with exercise stress, $946 for nuclear testing with exercise stress, and $1,132 for nuclear testing with pharmacologic stress, said Dr. Mark, director of outcomes research at Duke Clinical Research Institute, Durham, N.C.
The trend toward higher costs with CT angiography was driven largely by more revascularizations, with very in little added costs occurring after 90 days, he noted.
An analysis that factored in what was done to patients after their initial test showed CT angiography was more expensive than functional testing by an average of $279 at 90 days, $358 at 1 year, $388 at 2 years, and $694 at 3 years. The 95% confidence intervals were wide, so none of the differences were statistically significant, he said.
A number of patients underwent very expensive noncardiovascular procedures in the third year that bumped the average cost up in the CT arm, “but we don’t think this has anything to do with the strategies to which they were randomized,” Dr. Mark explained.
Caveats to the analysis include use of an external data source (Premier Research Database) for initial diagnostic testing costs, outpatient medications were not counted, and significant deviations in testing costs by centers that might alter cost results of the two strategies. Quality of life and employment status are also still being analyzed, Dr. Mark said.
A cost-effectiveness analysis was not performed because CT angiography outcomes were not superior as hypothesized in PROMISE.
The study was funded by the National Institutes of Health. Dr. Mark disclosed consulting for Milestone, Medtronic, CardioDx, and St. Jude Medical and research grants from the NIH, Eli Lilly, AstraZeneca, Gilead, AGA Medical, and Bristol-Myers Squibb.
SAN DIEGO– After the first 90 days, there is very little difference in costs out to 3 years between CT angiography and functional testing in the initial evaluation of stable patients with new chest pain, an economic substudy of the PROMISE trial showed.
“CT coronary angiography may not be the ‘holy grail’ of diagnostic tests that we once envisioned, but its more liberal use based on the results of PROMISE may improve some aspects of patient care and I don’t think will be a major new economic burden on the health care system,” study author Dr. Daniel B. Mark said at the annual meeting of the American College of Cardiology.
The PROMISE trial, also presented at the ACA meeting, found no advantage with respect to hard clinical outcomes between the two initial testing strategies, but CTA led to fewer catheterizations showing no obstructive disease and a twofold increase in revascularizations.
The economic analysis involved initial test technical fees, hospital-based facility costs, and physician professional fees for testing and hospital services for 96% of the 9,649 patients in the study.
The estimated cost of CT angiography, including physician fees and technical fees, was $404, compared with $174 for exercise treadmill testing, $501 for echocardiography with pharmacologic stress, $514 for echo with exercise stress, $946 for nuclear testing with exercise stress, and $1,132 for nuclear testing with pharmacologic stress, said Dr. Mark, director of outcomes research at Duke Clinical Research Institute, Durham, N.C.
The trend toward higher costs with CT angiography was driven largely by more revascularizations, with very in little added costs occurring after 90 days, he noted.
An analysis that factored in what was done to patients after their initial test showed CT angiography was more expensive than functional testing by an average of $279 at 90 days, $358 at 1 year, $388 at 2 years, and $694 at 3 years. The 95% confidence intervals were wide, so none of the differences were statistically significant, he said.
A number of patients underwent very expensive noncardiovascular procedures in the third year that bumped the average cost up in the CT arm, “but we don’t think this has anything to do with the strategies to which they were randomized,” Dr. Mark explained.
Caveats to the analysis include use of an external data source (Premier Research Database) for initial diagnostic testing costs, outpatient medications were not counted, and significant deviations in testing costs by centers that might alter cost results of the two strategies. Quality of life and employment status are also still being analyzed, Dr. Mark said.
A cost-effectiveness analysis was not performed because CT angiography outcomes were not superior as hypothesized in PROMISE.
The study was funded by the National Institutes of Health. Dr. Mark disclosed consulting for Milestone, Medtronic, CardioDx, and St. Jude Medical and research grants from the NIH, Eli Lilly, AstraZeneca, Gilead, AGA Medical, and Bristol-Myers Squibb.
SAN DIEGO– After the first 90 days, there is very little difference in costs out to 3 years between CT angiography and functional testing in the initial evaluation of stable patients with new chest pain, an economic substudy of the PROMISE trial showed.
“CT coronary angiography may not be the ‘holy grail’ of diagnostic tests that we once envisioned, but its more liberal use based on the results of PROMISE may improve some aspects of patient care and I don’t think will be a major new economic burden on the health care system,” study author Dr. Daniel B. Mark said at the annual meeting of the American College of Cardiology.
The PROMISE trial, also presented at the ACA meeting, found no advantage with respect to hard clinical outcomes between the two initial testing strategies, but CTA led to fewer catheterizations showing no obstructive disease and a twofold increase in revascularizations.
The economic analysis involved initial test technical fees, hospital-based facility costs, and physician professional fees for testing and hospital services for 96% of the 9,649 patients in the study.
The estimated cost of CT angiography, including physician fees and technical fees, was $404, compared with $174 for exercise treadmill testing, $501 for echocardiography with pharmacologic stress, $514 for echo with exercise stress, $946 for nuclear testing with exercise stress, and $1,132 for nuclear testing with pharmacologic stress, said Dr. Mark, director of outcomes research at Duke Clinical Research Institute, Durham, N.C.
The trend toward higher costs with CT angiography was driven largely by more revascularizations, with very in little added costs occurring after 90 days, he noted.
An analysis that factored in what was done to patients after their initial test showed CT angiography was more expensive than functional testing by an average of $279 at 90 days, $358 at 1 year, $388 at 2 years, and $694 at 3 years. The 95% confidence intervals were wide, so none of the differences were statistically significant, he said.
A number of patients underwent very expensive noncardiovascular procedures in the third year that bumped the average cost up in the CT arm, “but we don’t think this has anything to do with the strategies to which they were randomized,” Dr. Mark explained.
Caveats to the analysis include use of an external data source (Premier Research Database) for initial diagnostic testing costs, outpatient medications were not counted, and significant deviations in testing costs by centers that might alter cost results of the two strategies. Quality of life and employment status are also still being analyzed, Dr. Mark said.
A cost-effectiveness analysis was not performed because CT angiography outcomes were not superior as hypothesized in PROMISE.
The study was funded by the National Institutes of Health. Dr. Mark disclosed consulting for Milestone, Medtronic, CardioDx, and St. Jude Medical and research grants from the NIH, Eli Lilly, AstraZeneca, Gilead, AGA Medical, and Bristol-Myers Squibb.
AT ACC 2015
Evidence builds for complete revascularization in STEMI
SAN DIEGO– Complete revascularization of multivessel disease in patients hospitalized for ST-segment elevation MI improves long-term outcomes, although PCI of the culprit lesion only remains an option for some, the DANAMI3-PRIMULTI trial results suggest.
At 1 year, fractional flow reserve–guided complete revascularization significantly reduced the risk of all-cause death, nonfatal MI, and repeat revascularization, from 22% with infarct-only percutaneous coronary intervention (PCI) to 13%.
The reduction in the primary composite endpoint, however, was driven only by the need for fewer repeat revascularizations of non–infarct-related artery (IRA) lesions and not by hard endpoints.
“Therefore, although complete revascularization should be recommended, any condition that makes complex PCI unattractive may support a more conservative strategy of IRA PCI only,” principal investigator Thomas Engstrøm said at the American College of Cardiology/Cardiovascular Research Foundation Innovation in Intervention Summit.
Current guidelines support IRA-only PCI, although two contemporary studies – PRAMI and CvLPRIT – suggest that a preventive strategy of revascularization of all lesions in the coronary arteries improves outcomes, he noted.
DANAMI3-PRIMULTI (Third Danish Study of Optimal Acute Treatment of Patients With ST-Segment Elevation Myocardial Infarction: Primary PCI in Multivessel Disease) is the largest trial to date to examine this issue.
Investigators at two centers randomized 2,239 patients within 12 hours of STEMI to conventional primary PCI, ischemic postconditioning, or deferred stenting. Among 2,212 patients who had successful infarct-related artery PCI, 627 had multivessel disease and were further randomized to IRA PCI only or fractional flow reserve-guided complete revascularization. Multivessel disease was defined as greater than 50% stenosis in a non-IRA artery greater than 2 mm suitable for PCI.
Nonfatal MI occurred in 5% of patients in both groups, and all-cause death occurred in 4% of IRA-only patients and 5% of complete revascularization patients, reported Dr. Engstrøm, consultant cardiologist, Rigshospitalet, University of Copenhagen.
Ischemia-driven revascularizations were significantly more common in the IRA-only group, at 17%, compared with 5% in complete revascularization group, a significant difference. Notably, 40% of these repeat revascularizations were urgent on the basis of unstable angina, he said.
Panelist Sunil V. Rao, from Duke University in Durham, N.C., asked whether the knowledge that residual disease was left behind in half of the patients in the unblinded trial could potentially bias against the IRA-only arm.
Dr. Engstrøm acknowledged that “there may be a bias when the patients leave the hospital and know they have stenoses that are untreated,” but said great care was taken in the design of the trial because “we wanted to stress quite precisely the wording of the guidelines, which state that repeat revascularization could be either due to subjective or objective ischemia and to answer this question.”
DANAMI3-PRIMULTI’s modest patient population sets the stage for larger, more conclusive studies, but in the meantime will have an interesting impact on the U.S. guideline recommendation, currently a class III recommendation and suggestive of harm for treating additional lesions in the setting of acute MI, Dr. David Kandzari, director of interventional cardiology at the Piedmont Heart Center in Atlanta, said.
Dr. Kandzari echoed concerns that awareness of residual disease may have influenced the likelihood of repeat revascularizations, but also complimented the investigators on a thoughtful trial design that selected lesions based on clinically significant criteria and allowed non-infarct–related arteries to be treated in a staged fashion rather than mandating treatment at the time of PCI.
There was only one death between the index procedure and the additional PCI and this was caused by a cardiac rupture, and thus merely a result of the disease itself and not the staged approach, Dr. Engstrøm said in an interview.
“Of course, you can argue that full revascularization at the time of the index lesion may support even the IRA territory resulting in smaller final infarcts,” he added. “We find this, however, unlikely since both groups ended up with quite small infarct sequelae: LVEF 50% in both groups.”
Panelist Theodore A. Bass, chief of cardiology at the University of Florida in Jacksonville, said the trial “further confirms emerging data that in the same setting, or at least the same hospitalization, more aggressive treatment may be warranted in certain patients.”
“Our data support that complete revascularization can be done without harm and with a very good outcome,” Dr. Engstrøm said. “So you might argue: Why wait for the readmission either in the case of stable angina or in the indication of unstable angina with a need for urgent PCI?”
Dr. Engstrøm reported having no financial disclosures. Dr. Rao reported consulting fees/honoraria from Terumo Medical and the Medicines Company and research grants from Bellerophon Therapeutics. Dr. Kandzari reported consultant fees/honoraria from Boston Scientific, Medtronic, Micell Technologies, and Thoratec. Dr. Bass reported consulting fees/honoraria from Merck.
SAN DIEGO– Complete revascularization of multivessel disease in patients hospitalized for ST-segment elevation MI improves long-term outcomes, although PCI of the culprit lesion only remains an option for some, the DANAMI3-PRIMULTI trial results suggest.
At 1 year, fractional flow reserve–guided complete revascularization significantly reduced the risk of all-cause death, nonfatal MI, and repeat revascularization, from 22% with infarct-only percutaneous coronary intervention (PCI) to 13%.
The reduction in the primary composite endpoint, however, was driven only by the need for fewer repeat revascularizations of non–infarct-related artery (IRA) lesions and not by hard endpoints.
“Therefore, although complete revascularization should be recommended, any condition that makes complex PCI unattractive may support a more conservative strategy of IRA PCI only,” principal investigator Thomas Engstrøm said at the American College of Cardiology/Cardiovascular Research Foundation Innovation in Intervention Summit.
Current guidelines support IRA-only PCI, although two contemporary studies – PRAMI and CvLPRIT – suggest that a preventive strategy of revascularization of all lesions in the coronary arteries improves outcomes, he noted.
DANAMI3-PRIMULTI (Third Danish Study of Optimal Acute Treatment of Patients With ST-Segment Elevation Myocardial Infarction: Primary PCI in Multivessel Disease) is the largest trial to date to examine this issue.
Investigators at two centers randomized 2,239 patients within 12 hours of STEMI to conventional primary PCI, ischemic postconditioning, or deferred stenting. Among 2,212 patients who had successful infarct-related artery PCI, 627 had multivessel disease and were further randomized to IRA PCI only or fractional flow reserve-guided complete revascularization. Multivessel disease was defined as greater than 50% stenosis in a non-IRA artery greater than 2 mm suitable for PCI.
Nonfatal MI occurred in 5% of patients in both groups, and all-cause death occurred in 4% of IRA-only patients and 5% of complete revascularization patients, reported Dr. Engstrøm, consultant cardiologist, Rigshospitalet, University of Copenhagen.
Ischemia-driven revascularizations were significantly more common in the IRA-only group, at 17%, compared with 5% in complete revascularization group, a significant difference. Notably, 40% of these repeat revascularizations were urgent on the basis of unstable angina, he said.
Panelist Sunil V. Rao, from Duke University in Durham, N.C., asked whether the knowledge that residual disease was left behind in half of the patients in the unblinded trial could potentially bias against the IRA-only arm.
Dr. Engstrøm acknowledged that “there may be a bias when the patients leave the hospital and know they have stenoses that are untreated,” but said great care was taken in the design of the trial because “we wanted to stress quite precisely the wording of the guidelines, which state that repeat revascularization could be either due to subjective or objective ischemia and to answer this question.”
DANAMI3-PRIMULTI’s modest patient population sets the stage for larger, more conclusive studies, but in the meantime will have an interesting impact on the U.S. guideline recommendation, currently a class III recommendation and suggestive of harm for treating additional lesions in the setting of acute MI, Dr. David Kandzari, director of interventional cardiology at the Piedmont Heart Center in Atlanta, said.
Dr. Kandzari echoed concerns that awareness of residual disease may have influenced the likelihood of repeat revascularizations, but also complimented the investigators on a thoughtful trial design that selected lesions based on clinically significant criteria and allowed non-infarct–related arteries to be treated in a staged fashion rather than mandating treatment at the time of PCI.
There was only one death between the index procedure and the additional PCI and this was caused by a cardiac rupture, and thus merely a result of the disease itself and not the staged approach, Dr. Engstrøm said in an interview.
“Of course, you can argue that full revascularization at the time of the index lesion may support even the IRA territory resulting in smaller final infarcts,” he added. “We find this, however, unlikely since both groups ended up with quite small infarct sequelae: LVEF 50% in both groups.”
Panelist Theodore A. Bass, chief of cardiology at the University of Florida in Jacksonville, said the trial “further confirms emerging data that in the same setting, or at least the same hospitalization, more aggressive treatment may be warranted in certain patients.”
“Our data support that complete revascularization can be done without harm and with a very good outcome,” Dr. Engstrøm said. “So you might argue: Why wait for the readmission either in the case of stable angina or in the indication of unstable angina with a need for urgent PCI?”
Dr. Engstrøm reported having no financial disclosures. Dr. Rao reported consulting fees/honoraria from Terumo Medical and the Medicines Company and research grants from Bellerophon Therapeutics. Dr. Kandzari reported consultant fees/honoraria from Boston Scientific, Medtronic, Micell Technologies, and Thoratec. Dr. Bass reported consulting fees/honoraria from Merck.
SAN DIEGO– Complete revascularization of multivessel disease in patients hospitalized for ST-segment elevation MI improves long-term outcomes, although PCI of the culprit lesion only remains an option for some, the DANAMI3-PRIMULTI trial results suggest.
At 1 year, fractional flow reserve–guided complete revascularization significantly reduced the risk of all-cause death, nonfatal MI, and repeat revascularization, from 22% with infarct-only percutaneous coronary intervention (PCI) to 13%.
The reduction in the primary composite endpoint, however, was driven only by the need for fewer repeat revascularizations of non–infarct-related artery (IRA) lesions and not by hard endpoints.
“Therefore, although complete revascularization should be recommended, any condition that makes complex PCI unattractive may support a more conservative strategy of IRA PCI only,” principal investigator Thomas Engstrøm said at the American College of Cardiology/Cardiovascular Research Foundation Innovation in Intervention Summit.
Current guidelines support IRA-only PCI, although two contemporary studies – PRAMI and CvLPRIT – suggest that a preventive strategy of revascularization of all lesions in the coronary arteries improves outcomes, he noted.
DANAMI3-PRIMULTI (Third Danish Study of Optimal Acute Treatment of Patients With ST-Segment Elevation Myocardial Infarction: Primary PCI in Multivessel Disease) is the largest trial to date to examine this issue.
Investigators at two centers randomized 2,239 patients within 12 hours of STEMI to conventional primary PCI, ischemic postconditioning, or deferred stenting. Among 2,212 patients who had successful infarct-related artery PCI, 627 had multivessel disease and were further randomized to IRA PCI only or fractional flow reserve-guided complete revascularization. Multivessel disease was defined as greater than 50% stenosis in a non-IRA artery greater than 2 mm suitable for PCI.
Nonfatal MI occurred in 5% of patients in both groups, and all-cause death occurred in 4% of IRA-only patients and 5% of complete revascularization patients, reported Dr. Engstrøm, consultant cardiologist, Rigshospitalet, University of Copenhagen.
Ischemia-driven revascularizations were significantly more common in the IRA-only group, at 17%, compared with 5% in complete revascularization group, a significant difference. Notably, 40% of these repeat revascularizations were urgent on the basis of unstable angina, he said.
Panelist Sunil V. Rao, from Duke University in Durham, N.C., asked whether the knowledge that residual disease was left behind in half of the patients in the unblinded trial could potentially bias against the IRA-only arm.
Dr. Engstrøm acknowledged that “there may be a bias when the patients leave the hospital and know they have stenoses that are untreated,” but said great care was taken in the design of the trial because “we wanted to stress quite precisely the wording of the guidelines, which state that repeat revascularization could be either due to subjective or objective ischemia and to answer this question.”
DANAMI3-PRIMULTI’s modest patient population sets the stage for larger, more conclusive studies, but in the meantime will have an interesting impact on the U.S. guideline recommendation, currently a class III recommendation and suggestive of harm for treating additional lesions in the setting of acute MI, Dr. David Kandzari, director of interventional cardiology at the Piedmont Heart Center in Atlanta, said.
Dr. Kandzari echoed concerns that awareness of residual disease may have influenced the likelihood of repeat revascularizations, but also complimented the investigators on a thoughtful trial design that selected lesions based on clinically significant criteria and allowed non-infarct–related arteries to be treated in a staged fashion rather than mandating treatment at the time of PCI.
There was only one death between the index procedure and the additional PCI and this was caused by a cardiac rupture, and thus merely a result of the disease itself and not the staged approach, Dr. Engstrøm said in an interview.
“Of course, you can argue that full revascularization at the time of the index lesion may support even the IRA territory resulting in smaller final infarcts,” he added. “We find this, however, unlikely since both groups ended up with quite small infarct sequelae: LVEF 50% in both groups.”
Panelist Theodore A. Bass, chief of cardiology at the University of Florida in Jacksonville, said the trial “further confirms emerging data that in the same setting, or at least the same hospitalization, more aggressive treatment may be warranted in certain patients.”
“Our data support that complete revascularization can be done without harm and with a very good outcome,” Dr. Engstrøm said. “So you might argue: Why wait for the readmission either in the case of stable angina or in the indication of unstable angina with a need for urgent PCI?”
Dr. Engstrøm reported having no financial disclosures. Dr. Rao reported consulting fees/honoraria from Terumo Medical and the Medicines Company and research grants from Bellerophon Therapeutics. Dr. Kandzari reported consultant fees/honoraria from Boston Scientific, Medtronic, Micell Technologies, and Thoratec. Dr. Bass reported consulting fees/honoraria from Merck.
AT ACC/CRFi2
Key clinical point: Complete revascularization of multivessel disease in patients with STEMI improved long-term outcomes, but may not be the optimal strategy for all.
Major finding: Complete revascularization reduced the risk of the primary endpoint from 22% with infarct-only PCI to 13%.
Data source: Randomized trial in 627 STEMI patients with multivessel disease.
Disclosures: The presenter had no financial disclosures.
Thrombectomy fails to improve PCI outcomes, ups stroke risk
SAN DIEGO – Routine manual thrombectomy before percutaneous coronary intervention did not improve 180-day outcomes and was linked with an increased risk of stroke in patients with acute ST-segment elevation MI in the TOTAL trial.
Routine thrombectomy had no effect on the primary outcome of cardiovascular death, MI, cardiogenic shock, or New York Heart Association class IV heart failure, occurring in 6.9% of thrombectomy patients and 7% of PCI-only patients.
However, the study’s primary safety endpoint of stroke at 30 days doubled in patients undergoing routine thrombectomy before PCI to 33 events (0.7%), compared with those who had PCI with only bailout thrombectomy (16 events [0.3%]; P = .015).
The same pattern was observed with stroke or transient ischemic attack within 30 days (42 vs. 19 events; hazard ratio, 2.21; P = .003) and continued for stroke within 180 days (52 vs. 25 events; HR, 2.08; P = .002).
“The stroke findings are unexpected and we believe require confirmation in other datasets. A detailed case-by-case review is underway to help us understand the etiology and the relationship with the procedure,” lead author Dr. Sanjit S. Jolly said at the annual meeting of the American College of Cardiology.
Enthusiasm for manual thrombus aspiration was sparked by a survival benefit observed in the single-center, prospective TAPAS trial in ST-segment elevation MI patients (STEMI), and the procedure was widely adopted.
The more recent, multicenter TASTE trial, however, reported that routine thrombectomy before PCI failed to significantly reduce 30-day mortality in 7,244 STEMI patients, though there were trends toward reductions in stent thrombosis and hospitalization for recurrent MI.
TOTAL (Manual Aspiration Thrombectomy Plus PCI vs. PCI Alone in STEMI) randomly assigned 10,063 patients within 12 hours of STEMI symptoms to primary PCI either with upfront manual thrombectomy or only bailout thrombectomy if the PCI strategy failed.
The lack of significant differences between groups in the primary outcome was also true in all the components of the primary outcome. Furthermore, there was no effect on the primary outcome based on thrombotic burden, a question that remained unanswered after TASTE, Dr. Jolly reported. The TOTAL results were published online simultaneously with his report (N. Engl. J. Med. 2015 March 16 [doi:10.1056/NEJMoa1415098]).
“TOTAL and TASTE emphasize the need to conduct large randomized trials of common interventions, even when small trials appear positive,” Dr. Jolly said.
Discussant Dr. Steven Nissen, chair of cardiovascular medicine at Cleveland Clinic, described the routine use of thrombectomy as “a sad story about device regulation in the United States” in that the evidence level needed to get a medical device on the market is so far below that required for drug approval that patients undergo procedures without good randomized trial evidence to show they even work.
“We dodged a bullet recently with renal denervation when everyone thought it would work, and when you finally tested it, it didn’t,” Dr. Nissen said. “Let this be a lesson to us: We need to have more rigorous studies of medical devices before they get to market and get used in very large numbers of people.”
Currently, aspiration thrombectomy carries a IIa recommendation for use with PCI in the most recent ACC/American Heart Association guidelines for the management of patients with STEMI (J. Am. Coll. Cardiol. 2009;54:2205-41).
When asked whether the guidelines should change based on the TOTAL and TASTE results, Dr. Jolly said there should be a clear recommendation that routine thrombus aspiration should not be the appropriate approach, while the issue of bailout aspiration may be left to clinician judgment.
The finding of late strokes is difficult to understand and should be interpreted with caution because of the small number of strokes occurring between 30 and 180 days, he said. Detailed analysis of all strokes will be presented at a later meeting, but Rankin Scale scores show several strokes were “very debilitating.” There is a consistency in the data, as a meta-analysis of smaller trials also identified an increased stroke risk with adjunctive thrombectomy.
Discussant Dr. Gregg W. Stone, director of cardiovascular research and education at Columbia University Medical Center in New York, said a mechanism for periprocedural stroke with aspiration can be envisioned, but that understanding the risk of ongoing, late stroke is more difficult.
As for why thrombectomy didn’t work, “aspiration is incredibly inefficient, thromboemboli still occur before, during, and after aspiration, the timing of aspiration is often too late to benefit most patients,” and other mechanisms of myonecrosis may predominate, such as reperfusion injury, he observed.
Dr. Stone said the TOTAL results should change practice and that the guideline recommendation should be downgraded to IIb.
“There are some patients who have a very large thrombus burden who have trouble dealing with all that thrombus in the cath lab who might benefit, and it is impossible to design randomized trials for small sections and groups of patients,” he said. “I wouldn’t make it class III by any means, but I think it’ll take a long time for that reduction in use to actually transmit through clinical practice, because I must say interventional cardiologists love the idea of simply removing thrombus with a relatively easy-to-use device.”
Dr. David Kandzari, director of interventional cardiology at the Piedmont Heart Center in Atlanta, said in an interview that TOTAL will make operators much more selective and cautious in their performance of thrombectomy until further insights into the stroke issue are available. Thrombectomy should be reserved for bailout instances and not as a front-line therapy, he said.
On the other hand, the stroke rate in the early phase was not significantly different between groups in an as-treated analysis, and an opportunity exists to investigate potential differences between stroke and nonstroke patients to determine whether other comorbidities rather than thrombectomy per se may account for the stroke signal, Dr. Kandzari observed.
TOTAL was funded by the Canadian Institutes of Health Research, Canadian Network and Centre for Trials Internationally, and Medtronic. Dr. Jolly disclosed receiving consulting fees and honoraria from AstraZeneca, speaking fees for St. Jude, and research grants from Medtronic. Dr. Nissen has received research support from and is a consultant/adviser to numerous pharmaceutical companies; all honoraria or consulting fees go directly to charity so that he receives neither income nor a tax deduction. Dr. Stone reported consulting honoraria from Guided Delivery Systems, Miracor, and Reva, and ownership interest or partnership in Arstasis, Caliber, VNT, Micardia, Biostar family funds, and Medfocus family funds. Dr. Kandzari reported research and grant support from Medtronic, Biotronic, Abbott Vascular, and Boston Scientific.
SAN DIEGO – Routine manual thrombectomy before percutaneous coronary intervention did not improve 180-day outcomes and was linked with an increased risk of stroke in patients with acute ST-segment elevation MI in the TOTAL trial.
Routine thrombectomy had no effect on the primary outcome of cardiovascular death, MI, cardiogenic shock, or New York Heart Association class IV heart failure, occurring in 6.9% of thrombectomy patients and 7% of PCI-only patients.
However, the study’s primary safety endpoint of stroke at 30 days doubled in patients undergoing routine thrombectomy before PCI to 33 events (0.7%), compared with those who had PCI with only bailout thrombectomy (16 events [0.3%]; P = .015).
The same pattern was observed with stroke or transient ischemic attack within 30 days (42 vs. 19 events; hazard ratio, 2.21; P = .003) and continued for stroke within 180 days (52 vs. 25 events; HR, 2.08; P = .002).
“The stroke findings are unexpected and we believe require confirmation in other datasets. A detailed case-by-case review is underway to help us understand the etiology and the relationship with the procedure,” lead author Dr. Sanjit S. Jolly said at the annual meeting of the American College of Cardiology.
Enthusiasm for manual thrombus aspiration was sparked by a survival benefit observed in the single-center, prospective TAPAS trial in ST-segment elevation MI patients (STEMI), and the procedure was widely adopted.
The more recent, multicenter TASTE trial, however, reported that routine thrombectomy before PCI failed to significantly reduce 30-day mortality in 7,244 STEMI patients, though there were trends toward reductions in stent thrombosis and hospitalization for recurrent MI.
TOTAL (Manual Aspiration Thrombectomy Plus PCI vs. PCI Alone in STEMI) randomly assigned 10,063 patients within 12 hours of STEMI symptoms to primary PCI either with upfront manual thrombectomy or only bailout thrombectomy if the PCI strategy failed.
The lack of significant differences between groups in the primary outcome was also true in all the components of the primary outcome. Furthermore, there was no effect on the primary outcome based on thrombotic burden, a question that remained unanswered after TASTE, Dr. Jolly reported. The TOTAL results were published online simultaneously with his report (N. Engl. J. Med. 2015 March 16 [doi:10.1056/NEJMoa1415098]).
“TOTAL and TASTE emphasize the need to conduct large randomized trials of common interventions, even when small trials appear positive,” Dr. Jolly said.
Discussant Dr. Steven Nissen, chair of cardiovascular medicine at Cleveland Clinic, described the routine use of thrombectomy as “a sad story about device regulation in the United States” in that the evidence level needed to get a medical device on the market is so far below that required for drug approval that patients undergo procedures without good randomized trial evidence to show they even work.
“We dodged a bullet recently with renal denervation when everyone thought it would work, and when you finally tested it, it didn’t,” Dr. Nissen said. “Let this be a lesson to us: We need to have more rigorous studies of medical devices before they get to market and get used in very large numbers of people.”
Currently, aspiration thrombectomy carries a IIa recommendation for use with PCI in the most recent ACC/American Heart Association guidelines for the management of patients with STEMI (J. Am. Coll. Cardiol. 2009;54:2205-41).
When asked whether the guidelines should change based on the TOTAL and TASTE results, Dr. Jolly said there should be a clear recommendation that routine thrombus aspiration should not be the appropriate approach, while the issue of bailout aspiration may be left to clinician judgment.
The finding of late strokes is difficult to understand and should be interpreted with caution because of the small number of strokes occurring between 30 and 180 days, he said. Detailed analysis of all strokes will be presented at a later meeting, but Rankin Scale scores show several strokes were “very debilitating.” There is a consistency in the data, as a meta-analysis of smaller trials also identified an increased stroke risk with adjunctive thrombectomy.
Discussant Dr. Gregg W. Stone, director of cardiovascular research and education at Columbia University Medical Center in New York, said a mechanism for periprocedural stroke with aspiration can be envisioned, but that understanding the risk of ongoing, late stroke is more difficult.
As for why thrombectomy didn’t work, “aspiration is incredibly inefficient, thromboemboli still occur before, during, and after aspiration, the timing of aspiration is often too late to benefit most patients,” and other mechanisms of myonecrosis may predominate, such as reperfusion injury, he observed.
Dr. Stone said the TOTAL results should change practice and that the guideline recommendation should be downgraded to IIb.
“There are some patients who have a very large thrombus burden who have trouble dealing with all that thrombus in the cath lab who might benefit, and it is impossible to design randomized trials for small sections and groups of patients,” he said. “I wouldn’t make it class III by any means, but I think it’ll take a long time for that reduction in use to actually transmit through clinical practice, because I must say interventional cardiologists love the idea of simply removing thrombus with a relatively easy-to-use device.”
Dr. David Kandzari, director of interventional cardiology at the Piedmont Heart Center in Atlanta, said in an interview that TOTAL will make operators much more selective and cautious in their performance of thrombectomy until further insights into the stroke issue are available. Thrombectomy should be reserved for bailout instances and not as a front-line therapy, he said.
On the other hand, the stroke rate in the early phase was not significantly different between groups in an as-treated analysis, and an opportunity exists to investigate potential differences between stroke and nonstroke patients to determine whether other comorbidities rather than thrombectomy per se may account for the stroke signal, Dr. Kandzari observed.
TOTAL was funded by the Canadian Institutes of Health Research, Canadian Network and Centre for Trials Internationally, and Medtronic. Dr. Jolly disclosed receiving consulting fees and honoraria from AstraZeneca, speaking fees for St. Jude, and research grants from Medtronic. Dr. Nissen has received research support from and is a consultant/adviser to numerous pharmaceutical companies; all honoraria or consulting fees go directly to charity so that he receives neither income nor a tax deduction. Dr. Stone reported consulting honoraria from Guided Delivery Systems, Miracor, and Reva, and ownership interest or partnership in Arstasis, Caliber, VNT, Micardia, Biostar family funds, and Medfocus family funds. Dr. Kandzari reported research and grant support from Medtronic, Biotronic, Abbott Vascular, and Boston Scientific.
SAN DIEGO – Routine manual thrombectomy before percutaneous coronary intervention did not improve 180-day outcomes and was linked with an increased risk of stroke in patients with acute ST-segment elevation MI in the TOTAL trial.
Routine thrombectomy had no effect on the primary outcome of cardiovascular death, MI, cardiogenic shock, or New York Heart Association class IV heart failure, occurring in 6.9% of thrombectomy patients and 7% of PCI-only patients.
However, the study’s primary safety endpoint of stroke at 30 days doubled in patients undergoing routine thrombectomy before PCI to 33 events (0.7%), compared with those who had PCI with only bailout thrombectomy (16 events [0.3%]; P = .015).
The same pattern was observed with stroke or transient ischemic attack within 30 days (42 vs. 19 events; hazard ratio, 2.21; P = .003) and continued for stroke within 180 days (52 vs. 25 events; HR, 2.08; P = .002).
“The stroke findings are unexpected and we believe require confirmation in other datasets. A detailed case-by-case review is underway to help us understand the etiology and the relationship with the procedure,” lead author Dr. Sanjit S. Jolly said at the annual meeting of the American College of Cardiology.
Enthusiasm for manual thrombus aspiration was sparked by a survival benefit observed in the single-center, prospective TAPAS trial in ST-segment elevation MI patients (STEMI), and the procedure was widely adopted.
The more recent, multicenter TASTE trial, however, reported that routine thrombectomy before PCI failed to significantly reduce 30-day mortality in 7,244 STEMI patients, though there were trends toward reductions in stent thrombosis and hospitalization for recurrent MI.
TOTAL (Manual Aspiration Thrombectomy Plus PCI vs. PCI Alone in STEMI) randomly assigned 10,063 patients within 12 hours of STEMI symptoms to primary PCI either with upfront manual thrombectomy or only bailout thrombectomy if the PCI strategy failed.
The lack of significant differences between groups in the primary outcome was also true in all the components of the primary outcome. Furthermore, there was no effect on the primary outcome based on thrombotic burden, a question that remained unanswered after TASTE, Dr. Jolly reported. The TOTAL results were published online simultaneously with his report (N. Engl. J. Med. 2015 March 16 [doi:10.1056/NEJMoa1415098]).
“TOTAL and TASTE emphasize the need to conduct large randomized trials of common interventions, even when small trials appear positive,” Dr. Jolly said.
Discussant Dr. Steven Nissen, chair of cardiovascular medicine at Cleveland Clinic, described the routine use of thrombectomy as “a sad story about device regulation in the United States” in that the evidence level needed to get a medical device on the market is so far below that required for drug approval that patients undergo procedures without good randomized trial evidence to show they even work.
“We dodged a bullet recently with renal denervation when everyone thought it would work, and when you finally tested it, it didn’t,” Dr. Nissen said. “Let this be a lesson to us: We need to have more rigorous studies of medical devices before they get to market and get used in very large numbers of people.”
Currently, aspiration thrombectomy carries a IIa recommendation for use with PCI in the most recent ACC/American Heart Association guidelines for the management of patients with STEMI (J. Am. Coll. Cardiol. 2009;54:2205-41).
When asked whether the guidelines should change based on the TOTAL and TASTE results, Dr. Jolly said there should be a clear recommendation that routine thrombus aspiration should not be the appropriate approach, while the issue of bailout aspiration may be left to clinician judgment.
The finding of late strokes is difficult to understand and should be interpreted with caution because of the small number of strokes occurring between 30 and 180 days, he said. Detailed analysis of all strokes will be presented at a later meeting, but Rankin Scale scores show several strokes were “very debilitating.” There is a consistency in the data, as a meta-analysis of smaller trials also identified an increased stroke risk with adjunctive thrombectomy.
Discussant Dr. Gregg W. Stone, director of cardiovascular research and education at Columbia University Medical Center in New York, said a mechanism for periprocedural stroke with aspiration can be envisioned, but that understanding the risk of ongoing, late stroke is more difficult.
As for why thrombectomy didn’t work, “aspiration is incredibly inefficient, thromboemboli still occur before, during, and after aspiration, the timing of aspiration is often too late to benefit most patients,” and other mechanisms of myonecrosis may predominate, such as reperfusion injury, he observed.
Dr. Stone said the TOTAL results should change practice and that the guideline recommendation should be downgraded to IIb.
“There are some patients who have a very large thrombus burden who have trouble dealing with all that thrombus in the cath lab who might benefit, and it is impossible to design randomized trials for small sections and groups of patients,” he said. “I wouldn’t make it class III by any means, but I think it’ll take a long time for that reduction in use to actually transmit through clinical practice, because I must say interventional cardiologists love the idea of simply removing thrombus with a relatively easy-to-use device.”
Dr. David Kandzari, director of interventional cardiology at the Piedmont Heart Center in Atlanta, said in an interview that TOTAL will make operators much more selective and cautious in their performance of thrombectomy until further insights into the stroke issue are available. Thrombectomy should be reserved for bailout instances and not as a front-line therapy, he said.
On the other hand, the stroke rate in the early phase was not significantly different between groups in an as-treated analysis, and an opportunity exists to investigate potential differences between stroke and nonstroke patients to determine whether other comorbidities rather than thrombectomy per se may account for the stroke signal, Dr. Kandzari observed.
TOTAL was funded by the Canadian Institutes of Health Research, Canadian Network and Centre for Trials Internationally, and Medtronic. Dr. Jolly disclosed receiving consulting fees and honoraria from AstraZeneca, speaking fees for St. Jude, and research grants from Medtronic. Dr. Nissen has received research support from and is a consultant/adviser to numerous pharmaceutical companies; all honoraria or consulting fees go directly to charity so that he receives neither income nor a tax deduction. Dr. Stone reported consulting honoraria from Guided Delivery Systems, Miracor, and Reva, and ownership interest or partnership in Arstasis, Caliber, VNT, Micardia, Biostar family funds, and Medfocus family funds. Dr. Kandzari reported research and grant support from Medtronic, Biotronic, Abbott Vascular, and Boston Scientific.
AT ACC 2015
Key clinical point: Routine manual thrombectomy did not improve 180-day outcomes and increased the risk of stroke, compared with PCI alone.
Major finding: Thrombectomy plus PCI did not improve the primary outcome vs. PCI alone (6.9% vs. 7%) and doubled the 30-day stroke rate (0.7% vs. 0.3%).
Data source: Prospective study in 10,063 patients with STEMI.
Disclosures: TOTAL was funded by the Canadian Institutes of Health Research, Canadian Network and Centre for Trials Internationally, and Medtronic. Dr. Jolly disclosed receiving consulting fees and honoraria from AstraZeneca, speaking fees for St. Jude, and research grants from Medtronic.
U-tube drainage adds option for necrotizing pancreatitis
CHICAGO – Placement of a U-tube drain provides enhanced percutaneous drainage and minimizes catheter-related complications in patients with complicated or infected necrotizing pancreatitis, new research suggests.
The U-tube method uses a large, 20-French Silastic tube with numerous large holes in the middle. One exit must be anterior through the peritoneal cavity and the other can be posterior in the retroperitoneum, Dr. Daniel E. Abbott said at the annual meeting of the Central Surgical Association.
The novel drainage system allows bidirectional flushing, greater interface with large fluid collections leading to more rapid resolution of retroperitoneal necrosis, and less risk of dislodgement resulting in fewer catheter exchanges or replacements. The system also creates a large-bore fistula tract to fall back on should subsequent fistulojejunostomy be needed, said Dr. Abbott of the University of Cincinnati Medical Center.
He reported on the largest clinical experience with primary U-tube drainage to date, involving 22 patients with necrotizing pancreatitis (NP) treated from 2011 to 2014. In 7 patients, (32%) no surgical procedure was ultimately required.
Of the others, 13 required further surgical intervention for a disrupted duct, and (59%) 2 patients died (9.1% ), Dr. Abbott said. Among eight patients who underwent fistulojejunostomy and five who underwent distal pancreatectomy and/or splenectomy, NP resolved in all but one patient with a recurrent amylase-rich fluid leak.
This compares favorably with a 20% mortality rate and 80% NP resolution among five institutional controls treated with open necrosectomy, he said.
Dr. Abbott acknowledged that the study was limited by small numbers and an insufficient control group for direct comparison.
Other studies have shown mortality rates in NP ranging from 39% with open necrosectomy to 4.5% with focused open necrosectomy, but their median length of stays were 54.5 days and 57 days, respectively. LOS was trimmed to just 19 days in one open necrosectomy study (Ann. Surg. 2008;247:294-9), but mortality was 11.4%, Dr. Abbott observed.
Dr. Abbott’s center is currently placing one to two U-tubes per month in patients with symptomatic NP (nausea, vomiting, weight loss, or infection on radiographic imaging) amenable to drainage and plans to update the analysis with prospectively collected data, including costs, in 2-3 years, he said.
“The U-tube obviously seems to work very well, but ... our radiologists sometimes have a hard time placing just one single tube. That [U-]tube, in particular, has to come anterior and out posterior and other organs can potentially get in the way,” said Dr. Michael Ujiki, director of minimally invasive surgery at NorthShore University Health System, Evanston, Ill.
The morbidity and mortality rates are certainly better, but the improvements could be the result of improved ICU care or getting away from antibiotics, said Dr. Ujiki, a discussant at the meeting.
Dr. Abbott noted that “we are operating on people when they’re generally well instead of operating when they’re generally sick. When you’re doing an open necrosectomy, not only might there be multisystem organ failure, but [patients’] nutritional status is undoubtedly poor as well.”
Radiologists have yet to be unable to place a U-tube, but have delayed placement in stable, normotensive patients until fluid collections get larger to provide a better target, he said. The U-tube also can be placed at separate interventions. The two things patients complain most about are the size of the large tubes and when enzymatic fluid leaks onto their skin if the tube become clogged.
CHICAGO – Placement of a U-tube drain provides enhanced percutaneous drainage and minimizes catheter-related complications in patients with complicated or infected necrotizing pancreatitis, new research suggests.
The U-tube method uses a large, 20-French Silastic tube with numerous large holes in the middle. One exit must be anterior through the peritoneal cavity and the other can be posterior in the retroperitoneum, Dr. Daniel E. Abbott said at the annual meeting of the Central Surgical Association.
The novel drainage system allows bidirectional flushing, greater interface with large fluid collections leading to more rapid resolution of retroperitoneal necrosis, and less risk of dislodgement resulting in fewer catheter exchanges or replacements. The system also creates a large-bore fistula tract to fall back on should subsequent fistulojejunostomy be needed, said Dr. Abbott of the University of Cincinnati Medical Center.
He reported on the largest clinical experience with primary U-tube drainage to date, involving 22 patients with necrotizing pancreatitis (NP) treated from 2011 to 2014. In 7 patients, (32%) no surgical procedure was ultimately required.
Of the others, 13 required further surgical intervention for a disrupted duct, and (59%) 2 patients died (9.1% ), Dr. Abbott said. Among eight patients who underwent fistulojejunostomy and five who underwent distal pancreatectomy and/or splenectomy, NP resolved in all but one patient with a recurrent amylase-rich fluid leak.
This compares favorably with a 20% mortality rate and 80% NP resolution among five institutional controls treated with open necrosectomy, he said.
Dr. Abbott acknowledged that the study was limited by small numbers and an insufficient control group for direct comparison.
Other studies have shown mortality rates in NP ranging from 39% with open necrosectomy to 4.5% with focused open necrosectomy, but their median length of stays were 54.5 days and 57 days, respectively. LOS was trimmed to just 19 days in one open necrosectomy study (Ann. Surg. 2008;247:294-9), but mortality was 11.4%, Dr. Abbott observed.
Dr. Abbott’s center is currently placing one to two U-tubes per month in patients with symptomatic NP (nausea, vomiting, weight loss, or infection on radiographic imaging) amenable to drainage and plans to update the analysis with prospectively collected data, including costs, in 2-3 years, he said.
“The U-tube obviously seems to work very well, but ... our radiologists sometimes have a hard time placing just one single tube. That [U-]tube, in particular, has to come anterior and out posterior and other organs can potentially get in the way,” said Dr. Michael Ujiki, director of minimally invasive surgery at NorthShore University Health System, Evanston, Ill.
The morbidity and mortality rates are certainly better, but the improvements could be the result of improved ICU care or getting away from antibiotics, said Dr. Ujiki, a discussant at the meeting.
Dr. Abbott noted that “we are operating on people when they’re generally well instead of operating when they’re generally sick. When you’re doing an open necrosectomy, not only might there be multisystem organ failure, but [patients’] nutritional status is undoubtedly poor as well.”
Radiologists have yet to be unable to place a U-tube, but have delayed placement in stable, normotensive patients until fluid collections get larger to provide a better target, he said. The U-tube also can be placed at separate interventions. The two things patients complain most about are the size of the large tubes and when enzymatic fluid leaks onto their skin if the tube become clogged.
CHICAGO – Placement of a U-tube drain provides enhanced percutaneous drainage and minimizes catheter-related complications in patients with complicated or infected necrotizing pancreatitis, new research suggests.
The U-tube method uses a large, 20-French Silastic tube with numerous large holes in the middle. One exit must be anterior through the peritoneal cavity and the other can be posterior in the retroperitoneum, Dr. Daniel E. Abbott said at the annual meeting of the Central Surgical Association.
The novel drainage system allows bidirectional flushing, greater interface with large fluid collections leading to more rapid resolution of retroperitoneal necrosis, and less risk of dislodgement resulting in fewer catheter exchanges or replacements. The system also creates a large-bore fistula tract to fall back on should subsequent fistulojejunostomy be needed, said Dr. Abbott of the University of Cincinnati Medical Center.
He reported on the largest clinical experience with primary U-tube drainage to date, involving 22 patients with necrotizing pancreatitis (NP) treated from 2011 to 2014. In 7 patients, (32%) no surgical procedure was ultimately required.
Of the others, 13 required further surgical intervention for a disrupted duct, and (59%) 2 patients died (9.1% ), Dr. Abbott said. Among eight patients who underwent fistulojejunostomy and five who underwent distal pancreatectomy and/or splenectomy, NP resolved in all but one patient with a recurrent amylase-rich fluid leak.
This compares favorably with a 20% mortality rate and 80% NP resolution among five institutional controls treated with open necrosectomy, he said.
Dr. Abbott acknowledged that the study was limited by small numbers and an insufficient control group for direct comparison.
Other studies have shown mortality rates in NP ranging from 39% with open necrosectomy to 4.5% with focused open necrosectomy, but their median length of stays were 54.5 days and 57 days, respectively. LOS was trimmed to just 19 days in one open necrosectomy study (Ann. Surg. 2008;247:294-9), but mortality was 11.4%, Dr. Abbott observed.
Dr. Abbott’s center is currently placing one to two U-tubes per month in patients with symptomatic NP (nausea, vomiting, weight loss, or infection on radiographic imaging) amenable to drainage and plans to update the analysis with prospectively collected data, including costs, in 2-3 years, he said.
“The U-tube obviously seems to work very well, but ... our radiologists sometimes have a hard time placing just one single tube. That [U-]tube, in particular, has to come anterior and out posterior and other organs can potentially get in the way,” said Dr. Michael Ujiki, director of minimally invasive surgery at NorthShore University Health System, Evanston, Ill.
The morbidity and mortality rates are certainly better, but the improvements could be the result of improved ICU care or getting away from antibiotics, said Dr. Ujiki, a discussant at the meeting.
Dr. Abbott noted that “we are operating on people when they’re generally well instead of operating when they’re generally sick. When you’re doing an open necrosectomy, not only might there be multisystem organ failure, but [patients’] nutritional status is undoubtedly poor as well.”
Radiologists have yet to be unable to place a U-tube, but have delayed placement in stable, normotensive patients until fluid collections get larger to provide a better target, he said. The U-tube also can be placed at separate interventions. The two things patients complain most about are the size of the large tubes and when enzymatic fluid leaks onto their skin if the tube become clogged.
AT THE ANNUAL MEETING OF THE CENTRAL SURGICAL ASSOCIATION
Key clinical point: U-tube drainage may eliminate the need for surgery in severe necrotizing pancreatitis.
Major finding: Disease-specific mortality occurred in 2 of 22 patients.
Data source: Retrospective study of 22 patients with symptomatic and/or infected necrotizing pancreatitis.
Disclosures: The researchers reported having no financial conflicts.